https://www.synconaltd.com/ 2026-03-26T18:26:00+00:00 https://www.synconaltd.com/about/ 2026-02-05T07:51:22+00:00 https://www.synconaltd.com/about/who-we-are/ 2025-10-27T09:55:18+00:00 https://www.synconaltd.com/about/nav-growth-framework/ 2026-02-05T07:51:49+00:00 https://www.synconaltd.com/our-people/ 2025-10-06T09:52:27+00:00 https://www.synconaltd.com/our-people/melanie-gee/ 2025-06-10T11:22:48+00:00 https://www.synconaltd.com/our-people/chris-hollowood/ 2026-03-13T15:03:57+00:00 https://www.synconaltd.com/our-people/roel-bulthuis/ 2024-10-24T15:33:18+00:00 https://www.synconaltd.com/our-people/edward-hodgkin/ 2026-02-19T12:09:19+00:00 https://www.synconaltd.com/our-people/elisa-petris/ 2025-10-21T13:46:38+00:00 https://www.synconaltd.com/our-people/magdalena-jonikas/ 2026-02-26T09:31:16+00:00 https://www.synconaltd.com/our-people/gonzalo-garcia/ 2025-11-12T11:34:08+00:00 https://www.synconaltd.com/our-people/raghd-rostom/ 2025-12-17T11:49:07+00:00 https://www.synconaltd.com/our-people/nathaniel-dahan/ 2025-01-06T08:56:16+00:00 https://www.synconaltd.com/our-people/kenneth-galbraith/ 2025-04-09T08:41:35+00:00 https://www.synconaltd.com/our-people/annabel-clark/ 2025-06-11T14:41:56+00:00 https://www.synconaltd.com/our-people/kate-butler/ 2026-02-26T12:05:13+00:00 https://www.synconaltd.com/our-people/stephen-molumby/ 2025-10-21T13:45:39+00:00 https://www.synconaltd.com/our-people/christina-seed/ 2025-02-28T14:24:47+00:00 https://www.synconaltd.com/our-people/fiona-fernandez/ 2025-10-20T12:13:23+00:00 https://www.synconaltd.com/our-people/caroline-horsford/ 2025-02-28T14:24:42+00:00 https://www.synconaltd.com/our-people/gemma-mountford/ 2025-02-28T14:24:41+00:00 https://www.synconaltd.com/our-people/kemal-malik/ 2026-03-04T13:51:02+00:00 https://www.synconaltd.com/our-people/gian-piero-reverberi/ 2026-03-04T13:57:07+00:00 https://www.synconaltd.com/our-people/board-of-directors/ 2025-02-28T14:24:50+00:00 https://www.synconaltd.com/our-people/board-of-directors/melanie-gee/ 2025-06-16T11:31:03+00:00 https://www.synconaltd.com/our-people/board-of-directors/kemal-malik/ 2026-03-04T14:03:26+00:00 https://www.synconaltd.com/our-people/board-of-directors/gian-piero-reverberi/ 2026-03-04T14:02:41+00:00 https://www.synconaltd.com/our-people/board-of-directors/john-roche/ 2026-03-04T14:01:02+00:00 https://www.synconaltd.com/our-people/board-of-directors/julie-cherrington/ 2026-03-04T14:01:30+00:00 https://www.synconaltd.com/our-people/gwenaelle-pemberton/ 2025-06-16T09:11:56+00:00 https://www.synconaltd.com/our-people/ben-woolven/ 2025-02-28T14:24:45+00:00 https://www.synconaltd.com/our-people/nikki-padden/ 2025-06-11T14:07:49+00:00 https://www.synconaltd.com/our-people/william-dutson/ 2025-02-28T14:24:48+00:00 https://www.synconaltd.com/our-people/hitesh-thakrar/ 2026-01-15T15:03:09+00:00 https://www.synconaltd.com/our-people/alessio-d-addabbo/ 2025-02-28T14:24:44+00:00 https://www.synconaltd.com/our-people/pierre-joffrin/ 2025-02-28T14:24:47+00:00 https://www.synconaltd.com/our-people/harriet-gower-isaac/ 2025-06-11T13:01:43+00:00 https://www.synconaltd.com/our-people/richard-wooster/ 2025-02-28T14:24:45+00:00 https://www.synconaltd.com/our-people/helen-d-silva/ 2025-06-11T12:57:34+00:00 https://www.synconaltd.com/our-people/anastasia-prechistenskaya/ 2025-06-11T12:50:17+00:00 https://www.synconaltd.com/our-people/melina-hoffmann/ 2025-02-28T14:24:47+00:00 https://www.synconaltd.com/our-people/sarah-qian/ 2025-06-11T12:52:14+00:00 https://www.synconaltd.com/our-people/marc-perkins/ 2025-06-11T12:55:18+00:00 https://www.synconaltd.com/our-people/sarah-crabtree/ 2025-10-21T13:48:37+00:00 https://www.synconaltd.com/our-people/nisha-sethi/ 2025-02-28T14:24:43+00:00 https://www.synconaltd.com/our-people/samantha-roberts/ 2026-03-19T07:06:14+00:00 https://www.synconaltd.com/portfolio/ 2026-02-05T07:55:28+00:00 https://www.synconaltd.com/portfolio/commercial-companies/ 2026-02-05T08:23:55+00:00 https://www.synconaltd.com/portfolio/commercial-companies/autolus-therapeutics/ 2026-02-05T08:24:43+00:00 https://www.synconaltd.com/portfolio/late-stage-clinical-companies/ 2026-02-05T08:03:54+00:00 https://www.synconaltd.com/portfolio/late-stage-clinical-companies/beacon-therapeutics/ 2026-02-05T08:37:38+00:00 https://www.synconaltd.com/portfolio/late-stage-clinical-companies/beacon-therapeutics/lance-baldo/ 2024-09-05T15:53:24+00:00 https://www.synconaltd.com/portfolio/late-stage-clinical-companies/spur-therapeutics/ 2026-02-05T08:34:19+00:00 https://www.synconaltd.com/portfolio/late-stage-clinical-companies/spur-therapeutics/michael-parini/ 2025-06-19T07:11:46+00:00 https://www.synconaltd.com/portfolio/clinical-companies/ 2026-02-05T08:03:37+00:00 https://www.synconaltd.com/portfolio/clinical-companies/ionctura/ 2026-02-05T08:33:36+00:00 https://www.synconaltd.com/portfolio/clinical-companies/ionctura/catherine-pickering/ 2024-06-20T06:57:10+00:00 https://www.synconaltd.com/portfolio/clinical-companies/ionctura/lars-van-der-veen/ 2024-06-20T06:57:29+00:00 https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/ 2026-02-05T08:39:13+00:00 https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/iain-mcgill/ 2023-09-26T15:22:47+00:00 https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/prof-giovanna-lombardi/ 2023-09-26T15:22:46+00:00 https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/dr-marc-martinez-llordella/ 2023-09-26T15:22:48+00:00 https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/prof-alberto-sanchez-fueyo/ 2023-09-26T15:22:53+00:00 https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/prof-hans-stauss/ 2023-09-26T15:22:37+00:00 https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/prof-emma-morris/ 2023-09-26T15:22:44+00:00 https://www.synconaltd.com/portfolio/clinical-companies/quell-therapeutics/dr-elmar-jaeckel/ 2023-09-26T15:22:51+00:00 https://www.synconaltd.com/portfolio/clinical-companies/anaveon/ 2026-02-05T08:28:38+00:00 https://www.synconaltd.com/portfolio/clinical-companies/anaveon/andreas-katopodis/ 2025-06-19T06:53:48+00:00 https://www.synconaltd.com/portfolio/clinical-companies/mosaic-therapeutics/ 2026-02-05T08:28:55+00:00 https://www.synconaltd.com/portfolio/clinical-companies/mosaic-therapeutics/adrian-ibrahim/ 2025-06-19T07:18:30+00:00 https://www.synconaltd.com/portfolio/clinical-companies/mosaic-therapeutics/mathew-garnett/ 2025-06-19T07:18:29+00:00 https://www.synconaltd.com/portfolio/clinical-companies/mosaic-therapeutics/emile-voest/ 2025-06-19T07:18:29+00:00 https://www.synconaltd.com/portfolio/clinical-companies/mosaic-therapeutics/thomas-fuchs/ 2026-02-19T15:24:05+00:00 https://www.synconaltd.com/portfolio/clinical-companies/resolution-therapeutics/ 2026-02-05T08:29:20+00:00 https://www.synconaltd.com/portfolio/clinical-companies/resolution-therapeutics/amir-hefni/ 2025-06-19T07:18:30+00:00 https://www.synconaltd.com/portfolio/clinical-companies/resolution-therapeutics/prof-stuart-forbes/ 2025-06-19T07:18:29+00:00 https://www.synconaltd.com/portfolio/clinical-companies/resolution-therapeutics/prof-john-campbell/ 2025-06-19T07:18:29+00:00 https://www.synconaltd.com/portfolio/clinical-companies/purespring-therapeutics/ 2026-02-05T08:29:34+00:00 https://www.synconaltd.com/portfolio/clinical-companies/purespring-therapeutics/haseeb-ahmad/ 2026-02-19T15:02:18+00:00 https://www.synconaltd.com/portfolio/clinical-companies/purespring-therapeutics/moin-saleem/ 2023-09-26T15:22:44+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/ 2026-02-05T08:05:06+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/forcefield-therapeutics/ 2026-02-23T10:26:08+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/forcefield-therapeutics/mauro-giacca/ 2024-06-20T07:15:17+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/forcefield-therapeutics/dan-gliddon/ 2024-06-20T07:15:16+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/omass-therapeutics/ 2026-02-05T08:32:12+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/omass-therapeutics/ros-deegan/ 2023-09-26T15:22:58+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/omass-therapeutics/professor-dame-carol-robinson/ 2023-09-26T15:22:55+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/omass-therapeutics/dr-jonathan-hopper/ 2023-09-26T15:22:42+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/omass-therapeutics/dr-idlir-liko/ 2023-09-26T15:22:43+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/omass-therapeutics/hsin-yung-yen/ 2023-09-26T15:22:41+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/kesmalea-therapeutics/ 2026-02-05T08:33:12+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/kesmalea-therapeutics/harry-finch/ 2024-11-19T09:27:20+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/kesmalea-therapeutics/robert-johnson/ 2024-11-19T13:44:22+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/yellowstone-biosciences/ 2025-11-13T09:04:09+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/yellowstone-biosciences/professor-paresh-vyas/ 2024-08-14T08:32:01+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/yellowstone-biosciences/julian-hirst/ 2024-08-14T08:32:50+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/yellowstone-biosciences/jim-macdonald/ 2026-02-19T15:13:39+00:00 https://www.synconaltd.com/portfolio/pre-clinical-companies/slingshot-therapeutics/ 2025-11-13T09:04:37+00:00 https://www.synconaltd.com/portfolio/previous-portfolio-companies/ 2025-06-19T13:44:10+00:00 https://www.synconaltd.com/portfolio/previous-portfolio-companies/gyroscope-therapeutics/ 2024-10-07T10:59:31+00:00 https://www.synconaltd.com/portfolio/previous-portfolio-companies/blue-earth/ 2024-04-19T16:38:11+00:00 https://www.synconaltd.com/portfolio/previous-portfolio-companies/nightstar/ 2025-07-15T08:56:42+00:00 https://www.synconaltd.com/portfolio/previous-portfolio-companies/neogene-therapeutics/ 2024-04-19T16:38:12+00:00 https://www.synconaltd.com/portfolio/previous-portfolio-companies/14mg/ 2024-04-19T16:38:11+00:00 https://www.synconaltd.com/portfolio/previous-portfolio-companies/azeria-therapeutics/ 2025-07-09T10:05:34+00:00 https://www.synconaltd.com/portfolio/previous-portfolio-companies/clade-therapeutics/ 2024-04-19T16:53:06+00:00 https://www.synconaltd.com/sustainability/ 2025-07-02T06:31:29+00:00 https://www.synconaltd.com/sustainability/our-approach-to-sustainability-reporting/ 2025-07-02T06:32:53+00:00 https://www.synconaltd.com/sustainability/syncona-fellowship/ 2026-03-26T11:02:04+00:00 https://www.synconaltd.com/sustainability/sustainability-policies/ 2024-06-20T09:42:45+00:00 https://www.synconaltd.com/the-foundation/ 2025-05-07T11:47:35+00:00 https://www.synconaltd.com/the-foundation/alzheimer-s-research-uk/ 2023-07-11T15:55:41+00:00 https://www.synconaltd.com/the-foundation/alzheimer-s-society/ 2023-07-11T16:07:32+00:00 https://www.synconaltd.com/the-foundation/auditory-verbal-uk/ 2023-07-11T16:11:58+00:00 https://www.synconaltd.com/the-foundation/the-brain-tumour-charity/ 2023-07-11T16:21:04+00:00 https://www.synconaltd.com/the-foundation/breakthrough-t1d/ 2025-07-29T17:04:35+00:00 https://www.synconaltd.com/the-foundation/breast-cancer-now/ 2025-07-29T17:04:34+00:00 https://www.synconaltd.com/the-foundation/butterfly-thyroid-cancer-trust/ 2025-07-29T17:04:35+00:00 https://www.synconaltd.com/the-foundation/cure-leukaemia/ 2025-07-29T17:04:35+00:00 https://www.synconaltd.com/the-foundation/david-nott-foundation/ 2025-07-29T17:04:34+00:00 https://www.synconaltd.com/the-foundation/downside-up/ 2025-07-29T17:04:35+00:00 https://www.synconaltd.com/the-foundation/the-egmont-trust/ 2025-07-29T17:04:35+00:00 https://www.synconaltd.com/the-foundation/fight-for-sight/ 2025-07-29T17:04:36+00:00 https://www.synconaltd.com/the-foundation/generating-genius/ 2025-07-29T17:04:35+00:00 https://www.synconaltd.com/the-foundation/horatio-s-garden/ 2025-07-29T17:04:33+00:00 https://www.synconaltd.com/the-foundation/the-institute-of-cancer-research/ 2025-07-29T17:04:34+00:00 https://www.synconaltd.com/the-foundation/james-place/ 2025-07-29T17:04:34+00:00 https://www.synconaltd.com/the-foundation/great-ormond-street-hospital/ 2025-05-23T14:46:12+00:00 https://www.synconaltd.com/the-foundation/the-macular-society/ 2025-05-23T14:46:12+00:00 https://www.synconaltd.com/the-foundation/maggie-s/ 2025-05-23T14:46:13+00:00 https://www.synconaltd.com/the-foundation/marie-curie/ 2025-05-23T14:46:13+00:00 https://www.synconaltd.com/the-foundation/missing-people/ 2025-06-05T14:20:45+00:00 https://www.synconaltd.com/the-foundation/the-royal-marsden-cancer-charity/ 2025-06-05T14:20:45+00:00 https://www.synconaltd.com/the-foundation/supporting-wounded-veterans/ 2025-06-05T14:20:47+00:00 https://www.synconaltd.com/the-foundation/ssafa-the-armed-forces-charity/ 2025-06-05T14:20:45+00:00 https://www.synconaltd.com/the-foundation/place2be/ 2025-06-05T14:20:46+00:00 https://www.synconaltd.com/the-foundation/the-listening-place/ 2025-06-05T14:20:47+00:00 https://www.synconaltd.com/the-foundation/brainwaves/ 2025-06-05T14:20:46+00:00 https://www.synconaltd.com/the-foundation/the-ella-project/ 2025-06-05T14:20:45+00:00 https://www.synconaltd.com/the-foundation/tommy-s/ 2025-06-05T14:20:46+00:00 https://www.synconaltd.com/the-foundation/nmite/ 2025-06-18T09:17:20+00:00 https://www.synconaltd.com/the-foundation/ucl/ 2025-06-05T14:20:45+00:00 https://www.synconaltd.com/news-insights/ 2025-05-07T08:44:29+00:00 https://www.synconaltd.com/news-insights/news/ 2023-06-12T14:28:42+00:00 https://www.synconaltd.com/news-insights/news/nightstarx-commences-first-phase-i-ii-gene-therapy-clinical-trial-for-patients-with-x-linked-retinitis-pigmentosa/ 2025-10-20T15:33:32+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-receives-positive-chmp-opinion-for-axumin-fluciclovine-18f-for-pet-imaging-of-recurrent-prostate-cancer/ 2025-10-20T15:33:29+00:00 https://www.synconaltd.com/news-insights/news/making-a-difference-for-patients-with-recurrent-prostate-cancer/ 2025-10-20T15:33:34+00:00 https://www.synconaltd.com/news-insights/news/nightstarx-appoints-healthcare-finance-leader-senthil-sundaram-as-chief-financial-officerqqqqqqqqqqq/ 2023-11-14T10:33:12+00:00 https://www.synconaltd.com/news-insights/news/advanced-accelerator-applications-and-blue-earth-diagnostics-announce-european-manufacturing-and-distribution-agreements-for-axumin-fluciclovine-18f-for-pet-imaging-of-recurrent-prostate-cancer/ 2025-10-20T15:33:34+00:00 https://www.synconaltd.com/news-insights/news/nightstar-raises-45-million-to-fund-development-of-gene-therapies-for-blinding-retinal-diseases/ 2021-06-02T16:23:50+00:00 https://www.synconaltd.com/news-insights/news/freeline-therapeutics-appoints-anne-prener-as-chief-executive-officer/ 2025-10-20T15:33:29+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-expanded-leadership-team/ 2023-06-12T14:05:56+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-appoints-m2i-to-manufacture-and-distribute-axumin-in-ireland/ 2021-07-16T12:42:42+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-appoints-dr-soraya-bekkali-as-chief-executive-officer/ 2022-02-18T07:54:26+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-initial-results-from-falcon-trial-show-61-of-patients-with-suspected-recurrent-prostate-cancer-had-treatment-plan-changed-following-fluciclovine-18f-pet-ct-scan/ 2021-06-02T16:24:18+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-and-ge-healthcare-sign-uk-manufacturing-agreement/ 2021-06-02T16:10:24+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-and-seibersdorf-laboratories-announce-manufacturing-and-distribution-agreements-for-axumin-fluciclovine-18f-for-pet-imaging-of-recurrent-prostate-cancer/ 2021-06-02T16:24:42+00:00 https://www.synconaltd.com/news-insights/news/nightstar-therapeutics-to-participate-in-multiple-conferences-in-november/ 2025-10-20T15:33:28+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-publication-of-a-unique-therapeutic-approach-for-treatment-of-patients-with-t-cell-lymphomas-in-nature-medicine/ 2021-06-02T16:23:26+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-presentation-of-data-for-car-t-cells-with-reduced-sensitivity-to-checkpoint-inhibition-at-the-2017-american-society-of-hematology-annual-meeting/ 2021-07-16T13:01:32+00:00 https://www.synconaltd.com/news-insights/news/publication-of-pre-clinical-data-of-a-dual-targeting-car-for-treatment-of-multiple-myeloma/ 2021-06-02T16:23:09+00:00 https://www.synconaltd.com/news-insights/news/cell-and-gene-therapy-catapult-announces-viral-vector-manufacturing-technology-collaboration-with-freeline-therapeutics/ 2021-06-02T16:21:54+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-announces-presentation-at-upcoming-asco-2018-genitourinary-cancers-symposium-on-fluciclovine-18f-pet-ct-impact-on-clinical-management-of-recurrent-prostate-cancer/ 2025-10-20T15:33:35+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-announces-addition-of-axumin-fluciclovine-f-18-to-nccn-guidelines-for-pet-imaging-for-suspected-recurrent-prostate-cancer/ 2021-06-02T16:22:55+00:00 https://www.synconaltd.com/news-insights/news/former-chief-operating-officer-of-kite-pharma-cynthia-m-butitta-appointed-to-autolus-board-of-directors/ 2025-10-20T15:33:35+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-publication-in-molecular-therapy-on-its-small-molecule-activated-fast-acting-permanent-off-switchqqqqqqqqqqqqqqqqq/ 2024-01-08T18:17:09+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-oral-presentation-at-the-aacr-annual-meeting-of-a-phase-i-study-of-a-gd2-car-t-cell-therapy-in-patients-with-neuroblastoma/ 2021-06-02T16:01:36+00:00 https://www.synconaltd.com/news-insights/news/autolus-and-miltenyi-biotec-sign-strategic-supply-agreement/ 2025-10-20T15:33:34+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-presentation-of-preliminary-data-showing-early-signs-of-clinical-activity-for-a-gd2-targeting-car-t-cell-therapy-in-a-solid-tumour-setting-at-the-aacr-annual-meeting/ 2025-10-20T15:33:31+00:00 https://www.synconaltd.com/news-insights/news/nightstar-therapeutics-to-present-new-data-in-choroideremia-at-the-arvo-2018-annual-meeting/ 2023-06-12T14:05:56+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-license-agreement-with-ucl-business-plc-for-clinical-stage-product-candidate-in-development-for-the-treatment-of-b-cell-malignancies/ 2023-06-12T14:05:51+00:00 https://www.synconaltd.com/news-insights/news/results-from-blue-earth-diagnostics-locate-trial-show-59-of-patients-with-suspected-recurrent-prostate-cancer-had-change-in-management-plan-following-18f-fluciclovine-pet-ct-scan/ 2021-05-11T13:48:56+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-appointment-of-linda-bain-to-its-board-of-directors/ 2021-05-11T13:57:16+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-appointment-of-andrew-j-oakley-as-senior-vice-president-and-chief-financial-officer/ 2025-10-20T15:33:35+00:00 https://www.synconaltd.com/news-insights/news/syncona-expands-global-leadership-position-in-gene-therapy-with-foundation-of-new-companies/ 2025-10-20T15:33:32+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-appoints-iason-sp-z-o-o-to-manufacture-and-distribute-axumin-fluciclovine-18f-in-poland/ 2021-05-11T16:41:31+00:00 https://www.synconaltd.com/news-insights/news/nightstar-seeking-to-deliver-a-cure-for-choroideremia/ 2023-06-12T14:05:54+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-shortlisted-for-prestigious-best-emerging-biotech-company-award/ 2025-10-20T15:33:28+00:00 https://www.synconaltd.com/news-insights/news/nightstar-reports-q2-2018-financial-results/ 2025-10-20T15:33:33+00:00 https://www.synconaltd.com/news-insights/news/autolus-to-present-at-upcoming-investor-conferences/ 2025-10-20T15:33:32+00:00 https://www.synconaltd.com/news-insights/news/the-journal-of-urology-publishes-results-from-blue-earth-diagnostics-locate-trial-of-role-of-18f-fluciclovine-pet-ct-imaging-in-the-management-of-men-with-recurrent-prostate-cancer/ 2021-06-02T16:22:31+00:00 https://www.synconaltd.com/news-insights/news/nightstar-appoints-strategic-biotechnology-executive-paula-cobb-to-its-board-of-directors/ 2025-10-20T15:33:33+00:00 https://www.synconaltd.com/news-insights/news/achilles-announces-appointment-of-immuno-oncology-industry-leader-michael-f-giordano-m-d-to-its-board-of-directors/ 2025-10-20T15:33:35+00:00 https://www.synconaltd.com/news-insights/news/nightstar-therapeutics-to-present-at-2018-cell-gene-meeting-on-the-mesa/ 2021-06-02T16:19:34+00:00 https://www.synconaltd.com/news-insights/news/axumin-fluciclovine-18f-receives-positive-recommendation-from-transparency-committee-of-the-french-has-for-use-in-pet-imaging-of-suspected-recurrent-prostate-cancer/ 2021-07-16T11:31:29+00:00 https://www.synconaltd.com/news-insights/news/nightstar-therapeutics-to-present-at-chardan-genetic-medicines-conference/ 2021-06-02T16:19:48+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-wins-prestigious-best-emerging-biotech-award/ 2021-06-02T16:20:04+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-announces-fluciclovine-f-18-research-presentations-at-upcoming-astro-annual-meeting/ 2021-06-02T16:19:07+00:00 https://www.synconaltd.com/news-insights/news/nightstar-therapeutics-to-participate-in-multiple-conferences-in-november-1/ 2023-06-12T14:06:05+00:00 https://www.synconaltd.com/news-insights/news/freeline-appoints-brian-m-silver-as-chief-financial-officer-and-head-of-corporate-development/ 2025-10-20T15:33:34+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-led-consortium-secures-innovate-uk-funding-to-develop-a-suspension-platform-for-cost-effective-manufacture-of-novel-aav-gene-therapies/ 2022-02-18T07:54:19+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-announces-18f-fluciclovine-research-presentation-at-upcoming-society-for-neuro-oncology-sno-annual-scientific-meeting/ 2021-06-02T16:18:17+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-announces-results-of-investigational-phase-3-blinded-image-evaluation-study-of-18f-fluciclovine-pet-imaging-in-glioma/ 2023-06-12T14:05:54+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-announces-14-million-series-a-financing-to-build-a-pipeline-of-proprietary-medicines/ 2021-06-03T11:22:53+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-expands-its-senior-leadership-team/ 2025-10-20T15:33:31+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-appoints-dr-edwin-moses-as-chairman-of-its-board-of-directors-and-dr-iraj-ali-as-chief-executive-officer/ 2025-10-20T15:33:31+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-announces-u-s-food-and-drug-administration-fda-filing-acceptance-of-supplemental-new-drug-application-snda-for-18f-fluciclovine-pet-imaging-in-glioma/ 2021-06-02T16:17:03+00:00 https://www.synconaltd.com/news-insights/news/first-production-and-administration-of-axumin-fluciclovine-18f-in-france/ 2021-06-02T16:16:46+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-enters-lease-with-alexandria-real-estate-equities-inc-for-future-commercial-scale-manufacturing-site-and-u-s-headquarters/ 2021-07-16T11:15:37+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-receives-cta-approval-for-phase-i-ii-study-in-non-small-cell-lung-cancer/ 2021-06-02T16:15:56+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-new-program-for-gaucher-disease-and-poster-presentations-at-the-15th-annual-world-symposium-2019-in-orlando-usa/ 2021-06-02T16:15:37+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-announces-axumin-fluciclovine-f-18-locate-study-presentation-at-upcoming-asco-2019-genitourinary-cancers-symposium-on-impact-on-clinical-management-of-recurrent-prostate-cancer/ 2023-06-12T14:06:02+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-appoints-dr-markus-dangl-as-chief-scientific-officer/ 2025-10-20T15:33:33+00:00 https://www.synconaltd.com/news-insights/news/first-production-and-administration-of-axumin-fluciclovine-18f-in-italy/ 2021-07-16T11:21:41+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-receives-cta-approval-for-phase-i-ii-study-in-metastatic-or-recurrent-melanoma/ 2021-06-02T16:15:10+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-announces-first-patient-dosed-in-phase-i-ii-study-in-dry-amd/ 2022-02-18T07:54:13+00:00 https://www.synconaltd.com/news-insights/news/syncona-leads-chf-35-million-series-a-financing-in-anaveon-a-new-immuno-oncology-company/ 2021-06-02T10:37:23+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-new-data-on-auto1-at-the-american-association-of-cancer-research-aacr-annual-meeting-2019/ 2021-07-16T11:22:59+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-celebrates-five-year-anniversary/ 2025-10-20T15:33:28+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-announces-addition-of-axumin-fluciclovine-18f-to-eau-guidelines-for-imaging-in-patients-with-biochemical-recurrence-in-prostate-cancer/ 2021-07-16T11:32:36+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-receives-fda-orphan-drug-designation-for-auto3-for-treatment-of-acute-lymphoblastic-leukemia/ 2021-06-02T16:14:02+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-announces-presentations-on-axumin-fluciclovine-f-18-18f-fluciclovine-and-18f-rhpsma-at-upcoming-american-urological-association-s-2019-annual-meeting/ 2021-06-02T16:04:32+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-updates-on-the-company-s-aav-manufacturing-platform-at-the-american-society-of-gene-cell-therapy-asgct-22nd-annual-meeting/ 2021-06-02T16:07:06+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-the-implementation-of-the-pall-corporation-icellis-bioreactor-system-to-enable-commercial-scale-in-house-manufacturing-of-aav-gene-therapies/ 2021-06-02T16:13:34+00:00 https://www.synconaltd.com/news-insights/news/freeline-secures-long-term-commercial-manufacturing-capacity-at-brammer-bio-for-haemophilia-b-gene-therapy/ 2025-10-20T15:33:33+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-announces-results-from-initial-clinical-experience-of-18f-rhpsma-7-pet-imaging-by-technical-university-of-munich/ 2021-06-02T16:04:07+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-announces-results-of-additional-analyses-from-locate-trial-evaluating-change-in-recurrent-prostate-cancer-management-following-axumin-imaging/ 2021-06-02T16:04:15+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-appoints-rosamond-deegan-as-chief-executive-officer/ 2021-07-16T12:59:12+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-continues-to-expand-access-to-axumin-in-europe/ 2021-06-02T16:03:59+00:00 https://www.synconaltd.com/news-insights/news/consortium-led-by-freeline-with-partners-symbiosis-and-the-cell-and-gene-therapy-catapult-secure-funding-from-innovate-uk/ 2021-07-16T11:10:58+00:00 https://www.synconaltd.com/news-insights/news/freeline-presents-data-highlighting-platform-technology-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021/ 2021-06-02T15:07:48+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-data-at-the-american-society-of-gene-and-cell-therapy-annual-meeting-2021/ 2023-06-12T14:06:01+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-report-first-quarter-2021-financial-results-on-may-6/ 2021-06-04T16:26:19+00:00 https://www.synconaltd.com/news-insights/news/freeline-presents-preclinical-data-and-phase-1-2-study-design-of-the-flt190-aav-gene-therapy-for-fabry-disease-at-the-6th-update-on-fabry-disease-in-prague/ 2022-11-29T11:20:00+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-participate-in-upcoming-investor-conferences-in-june/ 2021-06-02T16:06:51+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-participate-in-upcoming-investor-conferences-in-april-and-may-2021/ 2023-06-12T14:06:02+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-receives-innovation-passport-and-entry-into-ilap-for-auto4-for-the-treatment-of-t-cell-receptor-constant-region-beta-chain-1-trbc1-positive-t-cell-lymphomas/ 2021-06-02T15:08:43+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-appoints-lisa-bright-to-its-board-of-directors/ 2021-06-02T10:43:50+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-appoints-jonathan-montagu-as-non-executive-director/ 2025-10-20T15:33:28+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-highlights-presentations-on-axumin-fluciclovine-f-18-18f-fluciclovine-and-18f-rhpsma-at-upcoming-society-of-nuclear-medicine-and-molecular-imaging-snmmi-annual-meeting/ 2023-06-12T14:06:03+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-senior-leadership-transition-and-completion-of-series-b-financing-milestones/ 2021-07-16T12:58:34+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-founded-by-syncona-ltd-appoints-chief-executive/ 2025-10-20T15:33:29+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-announces-results-from-investigational-clinical-study-of-safety-and-effectiveness-of-18f-fluciclovine-pet-imaging-in-adult-glioma/ 2021-06-02T16:04:50+00:00 https://www.synconaltd.com/news-insights/news/blue-earth-diagnostics-announces-highlights-of-technical-university-of-munich-presentations-on-initial-clinical-experience-with-18f-rhpsma-7-pet-imaging-in-high-risk-primary-and-biochemical-recurrent-prostate-cancer/ 2021-06-02T16:06:13+00:00 https://www.synconaltd.com/news-insights/news/freeline-presents-preclinical-liver-directed-aav-gene-therapy-data-at-the-european-working-group-on-gaucher-disease-ewggd/ 2021-06-02T16:03:37+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-publication-in-nature-medicine-of-data-supporting-the-development-of-auto1-for-treatment-of-patients-with-all/ 2022-11-29T11:19:50+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-updated-data-for-first-cohort-of-two-patients-in-haemophilia-b-study/ 2022-11-29T11:19:39+00:00 https://www.synconaltd.com/news-insights/news/freeline-doses-patient-in-first-fabry-disease-aav-gene-therapy-trial-globally/ 2021-06-02T16:02:51+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-named-a-fierce-15-company-by-fiercebiotech/ 2021-06-02T16:03:03+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-changes-to-executive-leadership-team/ 2021-07-16T12:58:02+00:00 https://www.synconaltd.com/news-insights/news/found-build-and-fund/ 2025-10-20T15:33:34+00:00 https://www.synconaltd.com/news-insights/news/founding-quell-therapeutics/ 2025-10-20T15:33:35+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-and-an-emerging-area-of-cell-therapy/ 2021-06-02T16:02:06+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-appoints-beverley-carr-as-chief-business-officer/ 2025-10-20T15:33:27+00:00 https://www.synconaltd.com/news-insights/news/an-introduction-to-gene-therapy/ 2021-06-02T16:01:17+00:00 https://www.synconaltd.com/news-insights/news/building-syncona-s-gene-therapy-platform/ 2021-06-02T16:01:11+00:00 https://www.synconaltd.com/news-insights/news/freeline-appoints-jeffrey-chodakewitz-m-d-to-its-board-of-directors/ 2025-10-20T15:33:28+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-receives-fda-orphan-drug-designation-for-auto1-for-treatment-of-acute-lymphoblastic-leukemia/ 2021-07-16T11:24:05+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-preclinical-data-on-aut06ng-at-the-sitc-annual-meeting/ 2023-06-12T14:06:00+00:00 https://www.synconaltd.com/news-insights/news/syncona-appoints-kenneth-galbraith-as-executive-in-residence/ 2021-06-02T10:38:49+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-receives-prime-designation-for-auto1-for-the-treatment-of-adult-all/ 2021-06-02T15:09:02+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-at-upcoming-investor-conferences-april/ 2021-06-02T10:37:43+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-announces-pricing-of-initial-public-offering/ 2021-06-04T16:21:16+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-updated-manufacturing-facility-strategy-leveraging-its-uk-operations/ 2021-06-02T15:09:33+00:00 https://www.synconaltd.com/news-insights/news/anaveon-receives-cta-approval-to-start-a-phase-i-ii-study-to-evaluate-the-safety-dosing-and-clinical-activity-of-anv419-in-patients-with-solid-tumors/ 2021-06-02T15:09:51+00:00 https://www.synconaltd.com/news-insights/news/swanbio-therapeutics-appoints-marita-james-cpa-as-chief-financial-officer/ 2023-06-12T14:06:05+00:00 https://www.synconaltd.com/news-insights/news/freeline-appoints-colin-love-phd-to-board-of-directors/ 2021-06-01T15:39:49+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-at-upcoming-investor-conferences/ 2021-06-02T15:14:18+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-appoints-jessica-stitt-as-chief-financial-officer/ 2023-06-12T14:05:59+00:00 https://www.synconaltd.com/news-insights/news/the-syncona-foundation-announces-301-500-donation-to-generating-genius/ 2021-06-01T15:50:54+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-at-the-h-c-wainwright-global-life-sciences-conference/ 2021-06-02T15:14:54+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-expansion-of-executive-leadership/ 2021-06-02T10:34:01+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-proposed-public-offering-in-the-united-states/ 2021-06-03T11:24:54+00:00 https://www.synconaltd.com/news-insights/news/freeline-presents-data-on-its-gaucher-disease-and-fabry-disease-aav-based-gene-therapies-at-the-17th-annual-worldsymposium/ 2022-11-29T11:19:32+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-report-fourth-quarter-and-full-year-2020-financial-results-and-host-conference-call-on-march-4/ 2021-06-02T10:43:30+00:00 https://www.synconaltd.com/news-insights/news/neogene-therapeutics-announces-ton-schumacher-ph-d-company-co-founder-awarded-2021-jeantet-collen-prize-for-translational-medicine/ 2021-06-02T10:34:59+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-data-at-the-2021-virtual-congress-of-the-european-association-for-haemophilia-and-allied-disorders-eahad-and-the-17th-annual-worldsymposium-2021/ 2021-06-02T15:15:38+00:00 https://www.synconaltd.com/news-insights/news/swanbio-therapeutics-appoints-alison-lawton-to-board-of-directors/ 2021-06-02T10:34:17+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-appoints-arjan-roozen-as-vp-site-head-and-general-manager/ 2021-06-02T10:39:36+00:00 https://www.synconaltd.com/news-insights/news/purespring-appoints-new-chief-executive-officer/ 2023-06-12T14:05:56+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference/ 2025-10-20T15:33:30+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-provides-business-outlook-for-2021-2022/ 2021-06-02T15:16:28+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-participate-at-conferences-during-january-2021/ 2021-06-02T15:16:12+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-participate-in-investor-conferences-through-january-2021/ 2021-06-02T15:17:09+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-and-the-university-of-pennsylvania-announce-research-agreement-to-develop-gene-therapies-for-serious-eye-diseases/ 2022-02-18T07:53:52+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-presents-preclinical-data-on-aut06ng-at-the-sitc-annual-meeting/ 2021-06-02T16:12:32+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-and-noile-immune-announce-licensing-agreement/ 2021-06-02T16:00:39+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-appoints-lee-m-stern-as-vp-ir-external-communications/ 2021-06-02T10:39:13+00:00 https://www.synconaltd.com/news-insights/news/professor-amit-nathwani-will-present-the-ham-wasserman-lecture-at-the-61st-ash-annual-meeting/ 2021-06-02T16:00:16+00:00 https://www.synconaltd.com/news-insights/news/freeline-appoints-julia-p-gregory-to-its-board-of-directors/ 2021-07-16T12:57:13+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference/ 2021-06-02T15:59:43+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-announces-appointments-of-industry-veterans-in-gene-therapy-ophthalmology-and-biopharmaceuticals-to-its-board-of-directors/ 2022-02-18T07:53:45+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference/ 2021-07-16T11:35:03+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-announces-a-26-6m-series-a-financing-from-syncona-ltd/ 2021-06-03T11:23:16+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-provide-outlook-for-2020-at-the-38th-annual-j-p-morgan-conference/ 2021-06-02T15:58:04+00:00 https://www.synconaltd.com/news-insights/news/autolus-chief-scientific-officer-dr-martin-pule-to-give-keynote-lecture-at-the-eha-ebmt-2nd-european-car-t-cell-meeting/ 2021-06-02T15:59:28+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-appoints-robert-coutts-as-chief-financial-officer/ 2025-10-20T15:33:30+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-closing-of-public-offering/ 2021-06-03T11:25:01+00:00 https://www.synconaltd.com/news-insights/news/lorenz-mayr-appointed-as-entrepreneur-in-residence/ 2021-07-16T12:56:46+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-publication-of-new-auto6-phase-1-data-in-childhood-neuroblastoma-in-science-translational-medicine/ 2023-06-12T14:06:04+00:00 https://www.synconaltd.com/news-insights/news/swanbio-therapeutics-expands-board-of-directors-with-appointments-of-proven-industry-leaders/ 2025-10-20T15:33:35+00:00 https://www.synconaltd.com/news-insights/news/freeline-appoints-theresa-heggie-as-chief-executive/ 2023-06-12T14:06:05+00:00 https://www.synconaltd.com/news-insights/news/syncona-founds-purespring-with-a-45m-series-a-financing/ 2025-10-20T15:33:29+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-data-on-aav-based-gene-therapies-for-fabry-disease-and-gaucher-disease-at-the-16th-annual-worldsymposium-2020/ 2021-06-02T15:59:16+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-strengthens-leadership-team-ahead-of-next-stage-of-company-growth/ 2022-02-18T07:53:38+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-announces-27-5-million-extended-series-a-financing/ 2025-10-20T15:33:32+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-at-the-3rd-annual-evercore-isi-health-conx-conference/ 2025-10-20T15:33:28+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-report-fourth-quarter-and-full-year-2019-financial-results-and-host-conference-call-on-march-3/ 2021-05-12T15:39:56+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto1-and-auto3-data-presented-at-ash-and-to-participate-in-the-jefferies-virtual-london-healthcare-conference/ 2021-06-02T15:23:33+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-announces-first-patient-dosed-in-phase-ii-horizon-trial-evaluating-investigational-gene-therapy-gt005-in-people-with-dry-age-related-macular-degeneration/ 2022-02-18T07:53:31+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-announces-grant-of-european-patent-covering-use-of-selectively-expanded-t-cells-targeting-clonal-neoantigens-for-the-treatment-of-cancer/ 2021-06-02T15:24:22+00:00 https://www.synconaltd.com/news-insights/news/anaveon-announces-presentation-at-the-2020-society-for-immunotherapy-of-cancer-sitc-annual-meeting/ 2021-06-02T15:26:22+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-third-quarter-2020-financial-results-and-operational-progress/ 2025-10-20T15:33:35+00:00 https://www.synconaltd.com/news-insights/news/omass-announces-acquisition-of-pharmacology-capabilities-from-excellerate-biosciences/ 2021-07-16T12:54:00+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-at-the-cowen-40th-annual-health-care-conference/ 2023-06-12T14:05:55+00:00 https://www.synconaltd.com/news-insights/news/freeline-receives-orphan-drug-designation-from-the-european-commission-for-flt190-for-the-treatment-of-fabry-disease/ 2021-06-02T15:58:47+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-appoints-professor-sergio-quezada-as-chief-scientific-officer/ 2025-10-20T15:33:33+00:00 https://www.synconaltd.com/news-insights/news/freeline-appoints-julie-krop-m-d-as-chief-medical-officer/ 2025-10-20T15:33:31+00:00 https://www.synconaltd.com/news-insights/news/covid-19-syncona-business-update/ 2025-10-20T15:33:32+00:00 https://www.synconaltd.com/news-insights/news/freeline-appoints-mark-baldry-as-chief-commercial-officer/ 2025-10-20T15:33:29+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-appoints-carsten-boess-to-the-board-of-directors/ 2025-10-20T15:33:31+00:00 https://www.synconaltd.com/news-insights/news/freeline-reports-half-year-2020-financial-results-and-recent-business-highlights/ 2025-10-20T15:33:28+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-enters-a-collaborative-research-agreement-with-the-hannover-medical-school/ 2021-06-02T15:57:21+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-to-present-a-manufacturing-update-at-the-virtual-2020-aacr-annual-meeting/ 2021-06-02T15:54:20+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-new-data-at-the-12th-annual-protein-and-antibody-engineering-summit/ 2021-06-01T15:58:31+00:00 https://www.synconaltd.com/news-insights/news/swanbio-therapeutics-announces-series-a-expansion-to-fund-its-lead-program-and-grow-pipeline-in-gene-therapy-for-neurological-diseases/ 2025-10-20T15:33:30+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-announces-first-patient-received-investigational-gene-therapy-gt005-via-orbit-subretinal-delivery-system-in-ongoing-phase-i-ii-focus-trial/ 2022-02-18T07:53:24+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-data-on-its-aav-gene-therapy-platform-and-programmes-at-the-23rd-annual-american-society-of-gene-cell-therapy-2020/ 2021-06-02T15:57:10+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-enters-a-collaborative-research-agreement-with-the-university-of-sheffield/ 2021-06-02T15:25:35+00:00 https://www.synconaltd.com/news-insights/news/danny-bar-zohar-joins-syncona-as-partner/ 2021-06-16T11:46:47+00:00 https://www.synconaltd.com/news-insights/news/twist-bioscience-and-neogene-announce-broad-strategic-partnership-for-next-generation-personalized-t-cell-therapies/ 2021-06-02T15:25:51+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-report-first-quarter-2020-financial-results-and-host-conference-call-on-may-7/ 2025-10-20T15:33:33+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-appoints-professor-karl-peggs-as-chief-medical-officer/ 2025-10-20T15:33:34+00:00 https://www.synconaltd.com/news-insights/news/freeline-receives-orphan-drug-designation-from-the-fda-for-flt190-for-the-treatment-of-fabry-disease/ 2021-06-02T15:56:59+00:00 https://www.synconaltd.com/news-insights/news/neogene-therapeutics-appoints-former-roche-chairman-and-chief-executive-officer-franz-b-humer-ph-d-as-executive-chairman-of-board-of-directors/ 2025-10-20T15:33:29+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-first-quarter-2020-financial-results-and-operational-progress/ 2025-10-20T15:33:31+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-announces-formation-of-scientific-advisory-board/ 2025-10-20T15:33:28+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-promotion-of-romuald-corbau-ph-d-to-chief-scientific-officer/ 2025-10-20T15:33:33+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-supply-agreement-for-haemophilia-b-program/ 2021-06-02T15:26:08+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-new-data-on-auto3-during-the-asco20-virtual-scientific-program/ 2022-11-29T11:18:53+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-granted-fda-fast-track-designation-for-gt005-an-investigational-gene-therapy-for-dry-age-related-macular-degeneration/ 2022-02-18T07:53:17+00:00 https://www.synconaltd.com/news-insights/news/omass-announces-publication-in-nature-methods/ 2021-06-02T15:55:27+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-new-data-on-auto1-and-auto3-at-the-2020-eha-annual-meeting/ 2022-11-29T11:18:59+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-new-data-at-the-virtual-2020-aacr-annual-meeting/ 2021-06-02T15:29:38+00:00 https://www.synconaltd.com/news-insights/news/neogene-therapeutics-raises-110-million-series-a-financing-to-develop-next-generation-fully-personalized-neo-antigen-t-cell-receptor-tcr-therapies/ 2021-06-01T15:37:38+00:00 https://www.synconaltd.com/news-insights/news/autolus-notice-of-annual-general-meeting-agm-on-thursday-june-18-2020/ 2021-06-02T15:55:13+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-announces-appointment-of-sean-bohen-to-the-board-of-directors/ 2022-02-18T07:53:10+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-host-investor-conference-calls-through-june/ 2021-06-02T15:54:59+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-participate-in-the-morgan-stanley-virtual-18th-annual-global-healthcare-conference/ 2021-06-02T15:28:39+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-host-investor-conference-call-to-discuss-auto3-data-presented-at-esmo-and-to-participate-in-banking-conferences-through-september/ 2021-06-02T15:27:51+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-doses-first-patient-in-phase-i-ii-study-in-recurrent-or-metastatic-malignant-melanoma-with-first-til-therapy-to-specifically-target-clonal-neoantigens/ 2021-06-02T15:54:40+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-announces-fda-clearance-for-orbit-subretinal-delivery-system/ 2022-02-18T07:09:47+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-presents-additional-data-on-auto3-in-dlbcl-during-the-asco20-virtual-scientific-program/ 2022-11-29T11:18:40+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-announces-initiation-of-phase-ii-programme-evaluating-its-investigational-gene-therapy-gt005-for-dry-age-related-macular-degeneration/ 2022-02-18T07:09:31+00:00 https://www.synconaltd.com/news-insights/news/swanbio-therapeutics-appoints-steven-zelenkofske-do-as-chief-medical-officer/ 2021-07-16T12:49:21+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-announces-appointment-of-leaders-in-retinal-disease-gene-therapy-and-the-complement-system-to-its-clinical-and-scientific-advisory-boards/ 2022-02-18T07:09:23+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-changes-to-its-board-and-management-team/ 2025-10-20T15:33:31+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reschedules-its-investor-eha-conference-call/ 2021-06-02T15:29:07+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-report-second-quarter-2020-financial-results-and-host-conference-call-on-august-6/ 2025-10-20T15:33:32+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-strengthens-its-board-with-the-appointments-of-dr-dhaval-patel-and-sir-robert-lechler-and-hires-dr-natalie-belmonte-as-svp-research-translation/ 2025-10-20T15:33:29+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-appoints-dr-nathalie-franchimont-as-non-executive-director/ 2025-10-20T15:33:35+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-presents-auto1-and-auto3-data-at-the-2020-eha25-virtual-congress/ 2022-11-29T11:18:33+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-presents-new-preclinical-data-during-the-virtual-2020-aacr-annual-meeting/ 2021-06-02T15:56:28+00:00 https://www.synconaltd.com/news-insights/news/freeline-files-registration-statement-for-proposed-initial-public-offering-in-the-united-states/ 2023-06-12T14:06:01+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-doses-first-patient-in-phase-i-ii-study-in-advanced-non-small-cell-lung-cancer/ 2021-06-02T15:55:41+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-acceptance-of-late-breaking-abstract-at-the-international-society-on-thrombosis-and-haemostasis-isth-2020-meeting/ 2025-10-20T15:33:30+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-additional-financing-plans/ 2025-10-20T15:33:31+00:00 https://www.synconaltd.com/news-insights/news/freeline-closes-120-million-series-c-financing-round/ 2025-10-20T15:33:32+00:00 https://www.synconaltd.com/news-insights/news/freeline-presents-new-haemophilia-b-data-at-the-international-society-on-thrombosis-and-haemostasis-isth-2020-meeting/ 2022-11-29T11:18:23+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-appoints-daniel-hood-as-chief-legal-officer/ 2025-10-20T15:33:32+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-participate-at-the-2021-rbc-capital-markets-global-healthcare-conference/ 2021-06-02T11:38:46+00:00 https://www.synconaltd.com/news-insights/news/swanbio-therapeutics-appoints-scott-mcmillan-ph-d-as-chief-technical-officer/ 2025-10-20T15:33:34+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-raises-52-7-million-in-an-oversubscribed-series-c-financing-to-further-advance-the-development-of-personalised-t-cell-therapies-to-treat-solid-tumours/ 2021-06-02T10:35:58+00:00 https://www.synconaltd.com/news-insights/news/nightstarx-appoints-ophthalmology-industry-veteran-scott-whitcup-to-board-of-directors/ 2025-10-20T15:33:29+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-an-additional-nature-publication-for-auto1/ 2023-06-12T14:05:59+00:00 https://www.synconaltd.com/news-insights/news/neogene-therapeutics-appoints-brent-pfeiffenberger-pharm-d-mba-as-chief-operating-officer/ 2021-06-07T16:36:04+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-innovation-licensing-and-access-pathway-ilap-designation-for-obe-cel-for-the-treatment-of-relapsed-refractory-adult-b-cell-all/ 2021-06-15T12:03:15+00:00 https://www.synconaltd.com/news-insights/news/freeline-doses-second-patient-of-phase-1-2-marvel-1-clinical-trial-for-fabry-disease/ 2021-06-16T12:14:43+00:00 https://www.synconaltd.com/news-insights/news/syncona-final-results-for-the-year-ended-31-march-2021/ 2021-07-08T09:21:37+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-announces-research-collaboration-agreement-with-children-s-medical-research-institute-to-develop-novel-gene-therapy-capsids/ 2022-02-18T07:09:11+00:00 https://www.synconaltd.com/news-insights/news/anaveon-doses-first-patient-in-a-phase-i-ii-study-to-evaluate-the-safety-dosing-and-clinical-activity-of-anv419-in-patients-with-solid-tumors/ 2021-07-08T09:20:29+00:00 https://www.synconaltd.com/news-insights/news/swanbio-therapeutics-announces-first-patient-enrolled-in-natural-history-study-to-evaluate-patients-with-adrenomyeloneuropathy/ 2021-07-08T09:20:18+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-executive-leadership-changes/ 2021-07-08T09:19:57+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-report-second-quarter-2021-financial-results-on-august-5-2021/ 2021-07-08T12:05:12+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-appointment-of-edgar-braendle-m-d-ph-d-as-chief-development-officer/ 2021-07-15T12:02:35+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-appoints-dominik-hartl-m-d-as-chief-medical-officer/ 2025-10-20T15:33:30+00:00 https://www.synconaltd.com/news-insights/news/autolus-and-moderna-sign-option-and-license-agreement-for-access-to-proprietary-targeting-technology-from-autolus/ 2021-08-02T12:02:32+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-second-quarter-2021-financial-results-and-operational-progress/ 2021-08-05T12:05:35+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-promising-innovative-medicine-pim-designation-for-obe-cel-for-the-treatment-of-relapsed-refractory-adult-b-cell-all/ 2021-08-09T12:05:30+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-reports-second-quarter-2021-financial-results-and-recent-business-highlights/ 2021-08-10T12:05:59+00:00 https://www.synconaltd.com/news-insights/news/freeline-provides-executive-leadership-team-update-company-to-provide-corporate-update-and-second-quarter-2021-financial-results-on-monday-august-16/ 2021-08-13T11:35:24+00:00 https://www.synconaltd.com/news-insights/news/freeline-appoints-michael-j-parini-as-chief-executive-officer-and-reports-second-quarter-2021-financial-results/ 2021-10-19T10:25:02+00:00 https://www.synconaltd.com/news-insights/news/syncona-announces-first-quarter-update/ 2023-06-12T14:05:54+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-publication-of-obe-cel-auto1-phase-1-allcar19-data-in-adults-with-relapsed-refractory-b-all-in-journal-of-clinical-oncology/ 2022-11-29T11:18:15+00:00 https://www.synconaltd.com/news-insights/news/purespring-strengthens-senior-leadership-with-appointment-of-chief-medical-officer-and-chief-development-officer/ 2023-06-12T14:05:51+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-participate-in-upcoming-investor-conferences-in-september-2021/ 2021-09-07T12:05:34+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-orphan-drug-designations-for-flt201-for-the-treatment-of-gaucher-disease/ 2021-09-16T12:12:28+00:00 https://www.synconaltd.com/news-insights/news/neogene-therapeutics-appoints-han-lee-ph-d-mba-as-chief-financial-officer/ 2021-09-16T12:12:11+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-the-appointment-of-john-h-johnson-as-non-executive-chairman-of-its-board-of-directors/ 2021-09-15T12:01:05+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-provides-an-update-on-its-manufacturing-facility-in-stevenage-uk/ 2021-09-16T12:11:54+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-significantly-expands-clinical-manufacturing-capacity-for-its-engineered-treg-cell-therapies-through-a-collaboration-with-the-cell-and-gene-therapy-catapult/ 2021-09-24T11:07:40+00:00 https://www.synconaltd.com/news-insights/news/swanbio-therapeutics-announces-new-preclinical-data-demonstrating-proof-of-principle-for-sbt101-gene-therapy-as-a-potential-treatment-of-adrenomyeloneuropathy/ 2021-10-19T11:26:24+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-presents-data-at-the-2021-european-society-for-gene-and-cell-therapy/ 2022-11-29T11:18:01+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-granted-cta-approval-to-begin-first-clinical-trial-with-a-multi-modular-engineered-treg-cell-therapy/ 2021-10-27T13:51:30+00:00 https://www.synconaltd.com/news-insights/news/clade-therapeutics-raises-87-million-series-a-financing-to-realise-the-potential-of-cell-therapy/ 2021-11-03T11:24:18+00:00 https://www.synconaltd.com/news-insights/news/cambridge-epigenetix-raises-88-million-series-d-financing-to-advance-best-in-class-dna-sequencing-technology-platform/ 2021-11-02T12:49:09+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-third-quarter-2021-financial-results-and-operational-progress/ 2021-11-03T11:05:57+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-new-data-at-the-63rd-ash-annual-meeting-exposition/ 2021-11-04T13:53:59+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4/ 2021-11-04T08:34:45+00:00 https://www.synconaltd.com/news-insights/news/omass-unveils-rich-drug-discovery-pipeline-targeting-intractable-or-inadequately-drugged-membrane-and-complex-bound-proteins/ 2021-11-04T08:39:20+00:00 https://www.synconaltd.com/news-insights/news/freeline-therapeutics-to-present-flt180a-data-at-the-2021-ash-annual-meeting/ 2021-11-04T13:11:29+00:00 https://www.synconaltd.com/news-insights/news/blackstone-life-sciences-to-invest-up-to-250-million-in-autolus-therapeutics-to-develop-obe-cel-in-adult-acute-lymphoblastic-leukemia-all-and-advance-broader-platform/ 2021-11-08T07:00:11+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-announces-sanofi-investment-of-up-to-60-million/ 2022-02-18T07:08:21+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-reports-third-quarter-2021-financial-results-and-recent-business-highlights/ 2021-12-01T16:40:21+00:00 https://www.synconaltd.com/news-insights/news/freeline-reports-new-data-from-fabry-disease-program-pipeline-and-company-updates-including-appointment-of-pamela-foulds-md-as-chief-medical-officer-and-third-quarter-2021-financial-results/ 2022-11-29T11:17:37+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-publication-describing-its-small-molecule-regulated-car-t-cells/ 2021-11-10T13:08:47+00:00 https://www.synconaltd.com/news-insights/news/syncona-interim-results-for-the-six-months-ended-30-september-2021/ 2021-11-11T07:02:40+00:00 https://www.synconaltd.com/news-insights/news/anaveon-announces-poster-presentation-at-the-2021-society-for-immunotherapy-of-cancer-annual-meeting/ 2021-11-12T12:05:11+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-presents-data-at-the-sitc-annual-meeting/ 2022-11-29T11:17:21+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-the-appointment-of-dr-william-d-young-as-a-non-executive-director/ 2021-11-15T12:03:34+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-raises-156-million-in-oversubscribed-series-b-financing-to-advance-its-pioneering-multi-modular-engineered-t-regulatory-treg-cell-therapy-pipeline-and-platform/ 2021-11-29T07:06:17+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announce-new-time-for-investor-call-to-discuss-data-presented-at-the-63rd-ash-annual-meeting-exposition/ 2021-12-06T13:33:08+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-announces-appointment-of-tony-adamis-to-board-of-directors/ 2022-02-18T07:08:08+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-presents-positive-data-at-esmo-i-o-congress-2021-on-high-dose-manufacturing-process-for-precision-t-cell-therapies-targeting-clonal-neoantigens/ 2022-11-29T11:17:04+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-presents-positive-obe-cel-data-at-the-63rd-ash-annual-meeting-exposition/ 2022-11-29T11:16:23+00:00 https://www.synconaltd.com/news-insights/news/freeline-presents-long-term-follow-up-data-from-phase-1-2-b-amaze-trial-in-hemophilia-b-at-the-2021-ash-annual-meeting/ 2022-11-29T11:16:41+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-2022-corporate-priorities-and-guidance/ 2021-12-23T09:28:42+00:00 https://www.synconaltd.com/news-insights/news/omass-founder-professor-dame-carol-robinson-honoured-with-the-2022-louis-jeantet-prize-for-medicine-and-the-2022-benjamin-franklin-medal-in-chemistry/ 2023-06-12T14:05:50+00:00 https://www.synconaltd.com/news-insights/news/anaveon-to-raise-chf-110-million-in-oversubscribed-series-b-financing/ 2021-12-16T12:53:03+00:00 https://www.synconaltd.com/news-insights/news/neogene-therapeutics-appoints-raphael-rousseau-m-d-ph-d-as-chief-medical-officer/ 2023-06-12T14:05:52+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-added-to-the-nasdaq-biotechnology-index/ 2021-12-20T14:19:18+00:00 https://www.synconaltd.com/news-insights/news/gyroscope-therapeutics-to-be-acquired-for-up-to-1-5-billion/ 2022-02-18T07:07:50+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-participate-in-conferences-during-january-2022/ 2023-06-12T14:06:01+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-at-conferences-during-january-2022/ 2022-01-05T12:05:53+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-fda-clearance-of-investigational-new-drug-application-for-flt201-for-gaucher-disease-type-1/ 2022-01-11T12:42:52+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-1/ 2022-01-07T09:49:03+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-2022-priorities/ 2022-01-11T12:42:40+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-retirement-of-chief-financial-officer-and-succession-plan/ 2022-01-11T12:42:29+00:00 https://www.synconaltd.com/news-insights/news/neogene-therapeutics-announces-exclusive-license-with-the-national-cancer-institute-for-a-portfolio-of-t-cell-receptors-tcr-targeting-kras-and-tp53-mutations-for-the-treatment-of-cancer/ 2022-01-11T13:10:03+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-provides-business-update-and-outlook-for-2022/ 2022-01-13T13:21:08+00:00 https://www.synconaltd.com/news-insights/news/swanbio-therapeutics-announces-fda-investigational-new-drug-clearance-for-first-aav-based-gene-therapy-for-the-treatment-of-adrenomyeloneuropathy/ 2022-01-25T12:34:20+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-on-its-fabry-and-gaucher-disease-aav-based-gene-therapies-at-the-18th-annual-worldsymposium/ 2022-01-28T00:11:27+00:00 https://www.synconaltd.com/news-insights/news/freeline-appoints-henning-r-stennicke-phd-as-chief-scientific-officer-to-lead-research-and-discovery/ 2022-02-03T12:06:21+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-2/ 2022-02-03T21:05:33+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-strengthens-scientific-advisory-board-with-appointment-of-alena-gros-ph-d-and-ben-creelan-m-d/ 2022-02-07T12:40:59+00:00 https://www.synconaltd.com/news-insights/news/freeline-presents-on-its-fabry-and-gaucher-disease-aav-based-gene-therapies-at-the-18th-annual-worldsymposiumtm/ 2022-11-29T11:14:18+00:00 https://www.synconaltd.com/news-insights/news/third-quarter-update/ 2022-02-10T07:02:11+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-strengthens-its-team-with-two-new-appointments/ 2022-02-17T08:00:05+00:00 https://www.synconaltd.com/news-insights/news/fda-grants-fast-track-designation-to-sbt101-the-first-investigational-aav-based-gene-therapy-for-patients-with-adrenomyeloneuropathy-amn/ 2022-02-17T12:55:41+00:00 https://www.synconaltd.com/news-insights/news/syncona-completes-sale-of-gyroscope-to-novartis/ 2022-03-04T09:48:32+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-report-fourth-quarter-and-full-year-2021-financial-results-and-host-conference-call-on-march-10/ 2022-02-21T12:05:59+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-to-present-at-upcoming-conferences/ 2022-02-21T09:50:08+00:00 https://www.synconaltd.com/news-insights/news/omass-s-odyssion-drug-discovery-platform-makes-progress-in-drugging-the-undruggable-including-gasdermin-d/ 2022-02-28T10:07:42+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-reports-fourth-quarter-and-year-end-2021-financial-results-and-recent-business-highlights/ 2023-06-12T14:05:57+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-publication-describing-novel-cell-programming-technology/ 2022-03-03T12:00:45+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-3/ 2023-06-12T14:05:57+00:00 https://www.synconaltd.com/news-insights/news/swanbio-therapeutics-to-present-new-preclinical-data-showcasing-aav-based-gene-therapy-candidate-for-adrenomyeloneuropathy-at-american-academy-of-neurology-annual-meeting/ 2023-06-12T14:06:06+00:00 https://www.synconaltd.com/news-insights/news/omass-establishes-scientific-advisory-board-of-leading-experts-in-the-use-of-biophysical-approaches-to-drug-discovery/ 2022-03-07T09:11:04+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-to-present-at-the-32nd-annual-oppenheimer-healthcare-conference/ 2022-03-08T13:08:07+00:00 https://www.synconaltd.com/news-insights/news/anaveon-to-present-first-clinical-data-from-the-phase-i-ii-study-of-anv419-at-the-aacr-annual-meeting-2022/ 2022-03-09T08:56:07+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-first-patient-dosed-in-the-phase-1-2-b-lieve-dose-confirmation-trial-in-hemophilia-b/ 2022-03-09T12:16:01+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-fourth-quarter-and-full-year-2021-financial-results-and-operational-progress/ 2022-03-10T12:03:13+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-26-1-million-registered-direct-offering-of-american-depositary-shares/ 2022-03-11T07:00:02+00:00 https://www.synconaltd.com/news-insights/news/fda-grants-orphan-drug-designation-to-sbt101-the-first-investigational-aav-based-gene-therapy-for-adrenomyeloneuropathy-amn/ 2022-03-15T14:14:58+00:00 https://www.synconaltd.com/news-insights/news/freeline-closes-26-1-million-registered-direct-offering-of-american-depositary-shares/ 2022-03-15T21:13:47+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-participate-in-upcoming-investor-conferences/ 2022-03-23T13:15:17+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-updated-development-plan-and-timelines-for-flt190-for-people-with-fabry-disease/ 2022-03-24T11:05:12+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-participate-in-conferences-during-april-2022/ 2022-03-29T12:03:43+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-receives-ema-orphan-medical-product-designation-for-obe-cel-for-treatment-of-acute-lymphoblastic-leukemia/ 2022-03-31T12:05:18+00:00 https://www.synconaltd.com/news-insights/news/freeline-reports-full-year-2021-financial-results-and-business-highlights/ 2022-04-01T07:00:34+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-to-host-kol-webcast-to-highlight-tracerx-study-presentations-from-the-2022-aacr-annual-meeting/ 2022-04-04T13:11:41+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-and-pancella-inc-announce-a-research-evaluation-option-agreement-to-develop-ipsc-derived-macrophage-cell-therapy-for-inflammatory-organ-disease/ 2022-04-05T07:10:14+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-announces-a-10m-extended-series-a-financing-from-syncona-ltd/ 2022-04-05T07:10:14+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-to-present-at-upcoming-conferences/ 2022-04-05T13:07:58+00:00 https://www.synconaltd.com/news-insights/news/updated-preclinical-data-support-potential-of-first-aav-based-gene-therapy-as-a-treatment-for-adrenomyeloneuropathy/ 2022-04-05T13:12:47+00:00 https://www.synconaltd.com/news-insights/news/publication-in-nature-by-omass-founder-professor-dame-carol-robinson-shows-power-of-native-mass-spectrometry-in-drug-discovery-by-capturing-gpcr-signalling-in-native-membrane-environment/ 2022-04-07T12:06:05+00:00 https://www.synconaltd.com/news-insights/news/anaveon-presents-compelling-data-from-the-phase-i-ii-study-of-anv419-during-the-aacr-annual-meeting-2022/ 2022-11-29T11:13:35+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-announces-manufacturing-expansion-in-the-uk-and-partnership-for-manufacturing-in-the-us/ 2022-04-12T13:02:52+00:00 https://www.synconaltd.com/news-insights/news/freeline-appoints-paul-schneider-as-chief-financial-officer/ 2022-04-19T13:03:40+00:00 https://www.synconaltd.com/news-insights/news/omass-ceo-ros-deegan-named-as-a-2022-in-vivo-rising-leader/ 2022-04-19T12:14:53+00:00 https://www.synconaltd.com/news-insights/news/forcefield-therapeutics-launches-today-following-5-5m-commitment-from-syncona/ 2023-06-12T14:05:57+00:00 https://www.synconaltd.com/news-insights/news/fda-grants-regenerative-medicine-advanced-therapy-rmat-designation-to-autolus-car-t-cell-therapy-obe-cel-for-the-treatment-of-adult-b-all/ 2022-04-25T12:05:30+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-report-first-quarter-2022-financial-results-and-host-conference-call-on-may-5/ 2022-04-25T12:05:30+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-and-cellistic-enter-a-strategic-collaboration-to-develop-an-ipsc-derived-allogeneic-t-regulatory-treg-cell-therapy-platform/ 2022-04-27T16:58:00+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-raises-100-million-in-series-b-financing-to-progress-drug-pipeline-in-immunology-and-rare-diseases/ 2023-06-12T14:05:55+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-at-the-25th-annual-meeting-of-the-american-society-of-gene-and-cell-therapy/ 2022-05-02T22:34:27+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-three-novel-cell-programming-approaches-at-the-american-society-of-gene-cell-therapy-asgct-25th-annual-meeting-may-16-19-2022/ 2022-05-02T22:33:29+00:00 https://www.synconaltd.com/news-insights/news/achilles-to-present-at-upcoming-conferences/ 2022-05-03T13:06:31+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-appoints-bernhard-ehmer-to-board-of-directors/ 2022-05-04T13:02:48+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-first-quarter-2022-financial-results-and-operational-progress/ 2022-05-05T12:05:14+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-doses-first-patient-with-higher-dose-cnet-in-phase-i-iia-chiron-trial-in-advanced-nsclc-and-initiates-enrollment-in-cohort-b-of-the-thetis-trial-cnet-pd-1-checkpoint-inhibitor-in-metastatic-malignant-melanoma/ 2022-05-09T12:31:17+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-reports-first-quarter-2022-financial-results-and-recent-business-highlights/ 2022-05-10T12:54:10+00:00 https://www.synconaltd.com/news-insights/news/neogene-therapeutics-announces-approval-of-clinical-trial-application-for-its-first-phase-1-trial-of-novel-fully-individualized-tcr-therapy-to-treat-advanced-solid-tumors/ 2022-05-10T13:03:43+00:00 https://www.synconaltd.com/news-insights/news/freeline-reports-first-quarter-2022-financial-results-and-business-highlights/ 2022-05-11T07:00:00+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-four-clinical-data-updates-at-the-european-hematology-association-congress/ 2022-05-12T16:04:13+00:00 https://www.synconaltd.com/news-insights/news/additional-preclinical-data-supports-clinical-advancement-of-first-aav-based-gene-therapy-for-adrenomyeloneuropathy/ 2022-05-17T13:56:41+00:00 https://www.synconaltd.com/news-insights/news/swanbio-therapeutics-announces-56-million-series-b-financing-to-advance-novel-gene-therapies-for-neurological-conditions/ 2022-05-18T11:11:34+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-participate-in-the-jefferies-healthcare-conference-being-held-in-new-york-from-june-8-10-2022/ 2022-06-02T10:50:44+00:00 https://www.synconaltd.com/news-insights/news/freeline-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement/ 2022-06-06T07:03:00+00:00 https://www.synconaltd.com/news-insights/news/anaveon-announces-fda-safe-to-proceed-letter-for-investigational-new-drug-ind-application-for-its-no-alpha-il-2-agonist-anv419/ 2023-06-12T14:06:04+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-presents-clinical-data-updates-at-the-european-hematology-association-congress/ 2023-06-12T14:05:58+00:00 https://www.synconaltd.com/news-insights/news/freeline-initiates-dosing-of-second-cohort-in-b-lieve-dose-confirmation-trial-of-flt180a-in-hemophilia-b/ 2022-06-14T12:21:43+00:00 https://www.synconaltd.com/news-insights/news/cambridge-epigenetix-names-peter-fromen-as-chief-executive-officer/ 2022-06-16T06:40:33+00:00 https://www.synconaltd.com/news-insights/news/syncona-final-year-results-for-the-year-ended-31-march-2022/ 2022-06-16T07:02:26+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-recognized-with-the-2022-ping-innovation-award/ 2022-06-21T13:53:29+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-new-clinical-data-for-flt180a-in-hemophilia-b-at-international-society-on-thrombosis-and-haemostasis-congress/ 2022-06-24T14:39:58+00:00 https://www.synconaltd.com/news-insights/news/swanbio-presents-design-of-innovative-natural-history-study-aimed-to-evolve-understanding-of-adrenomyeloneuropathy-and-inform-future-treatments/ 2022-06-27T21:09:10+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-appoints-dr-amol-ketkar-as-chief-development-officer/ 2022-06-30T13:08:44+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-appoints-james-taylor-as-chief-business-officer-and-cassian-yee-md-to-scientific-advisory-board/ 2022-06-30T13:16:32+00:00 https://www.synconaltd.com/news-insights/news/anaveon-appoints-dr-gary-phillips-as-chief-business-officer/ 2022-07-13T09:32:43+00:00 https://www.synconaltd.com/news-insights/news/purespring-therapeutics-and-swanbio-therapeutics-announce-licensing-agreement-for-use-of-funsel-screening-platform/ 2022-07-18T12:32:06+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-appoints-bill-symonds-to-its-board-of-directors/ 2022-07-20T10:00:10+00:00 https://www.synconaltd.com/news-insights/news/new-england-journal-of-medicine-publishes-positive-long-term-data-on-freeline-s-gene-therapy-candidate-flt180a-for-people-with-hemophilia-b/ 2023-06-12T14:05:52+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-report-second-quarter-2022-financial-results-on-august-4-2022/ 2022-07-21T17:58:44+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-to-lead-horizon-europe-funded-consortium-to-advance-personalized-cell-therapy-manufacturing/ 2022-07-21T13:13:12+00:00 https://www.synconaltd.com/news-insights/news/purespring-therapeutics-expands-senior-team-with-key-appointments/ 2022-07-26T12:49:18+00:00 https://www.synconaltd.com/news-insights/news/anaveon-to-present-new-data-from-the-phase-i-ii-study-of-anv419-at-the-esmo-congress-2022/ 2022-07-29T10:41:14+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-second-quarter-2022-financial-results-and-operational-progress/ 2022-08-04T12:07:34+00:00 https://www.synconaltd.com/news-insights/news/freeline-reports-second-quarter-2022-financial-results-and-business-highlights/ 2022-08-09T12:03:40+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-reports-second-quarter-2022-financial-results-and-recent-business-highlights/ 2022-08-09T12:03:45+00:00 https://www.synconaltd.com/news-insights/news/first-quarter-update/ 2022-08-16T07:12:43+00:00 https://www.synconaltd.com/news-insights/news/freeline-therapeutics-report-of-foreign-issuer-rules-13a-16-and-15d-16-of-the-securities-exchange-act/ 2022-08-30T07:00:38+00:00 https://www.synconaltd.com/news-insights/news/forcefield-therapeutics-researchers-identify-three-proteins-which-have-the-potential-to-prevent-heart-failure-after-heart-attack/ 2022-08-31T19:05:53+00:00 https://www.synconaltd.com/news-insights/news/anaveon-to-present-updated-data-from-phase-i-ii-study-of-anv419-at-esmo/ 2022-09-05T07:46:25+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-august-2022-inducement-grants-under-nasdaq-listing-rule-5635-c-4/ 2022-09-07T09:00:14+00:00 https://www.synconaltd.com/news-insights/news/purespring-therapeutics-strengthens-scientific-leadership-with-the-appointment-of-alice-brown-as-chief-scientific-officer/ 2022-09-07T15:27:13+00:00 https://www.synconaltd.com/news-insights/news/anaveon-presents-updated-data-from-the-phase-i-ii-study-of-anv419-during-the-esmo-congress-2022/ 2022-11-29T11:04:54+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-collaboration-with-bristol-myers-squibb-for-use-of-autolus-proprietary-safety-switch-system/ 2022-10-04T12:05:07+00:00 https://www.synconaltd.com/news-insights/news/freeline-initiates-dosing-of-second-cohort-in-marvel-1-trial-of-flt190-gene-therapy-candidate-for-people-with-fabry-disease/ 2022-10-04T12:05:07+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-september-2022-inducement-grants-under-nasdaq-listing-rule-5635-c-4/ 2022-10-05T21:05:33+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-co-founder-professor-charles-swanton-to-participate-in-expert-roundtable-highlighting-pivotal-nature-of-neoantigens-as-targets-in-cancer-cell-therapy/ 2022-10-06T15:31:32+00:00 https://www.synconaltd.com/news-insights/news/moderna-exercises-option-to-license-proprietary-targeting-technology-from-autolus/ 2022-10-12T12:05:59+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-report-third-quarter-2022-financial-results-on-november-3-2022/ 2022-10-21T12:12:12+00:00 https://www.synconaltd.com/news-insights/news/syncona-commences-tender-offer-for-all-outstanding-shares-of-applied-genetic-technologies-corporation/ 2022-10-27T07:05:56+00:00 https://www.synconaltd.com/news-insights/news/anaveon-announces-upcoming-poster-presentations-at-the-37th-society-for-immunotherapy-of-cancer-annual-meeting/ 2022-10-31T13:08:40+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-third-quarter-2022-financial-results-and-operational-progress/ 2022-11-03T11:13:54+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-three-clinical-data-updates-at-the-american-society-of-hematology-ash-annual-meeting-2022/ 2022-11-29T11:04:20+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-and-ccrm-sign-collaboration-agreement-to-develop-and-scale-up-manufacturing-for-induced-pluripotent-stem-cell-ipsc-derived-macrophage-cell-therapies/ 2022-11-07T09:49:40+00:00 https://www.synconaltd.com/news-insights/news/forcefield-therapeutics-presents-positive-preclinical-data-at-the-2022-scientific-sessions-of-american-heart-association/ 2022-11-29T11:20:53+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-announces-the-appointment-of-lisa-bright-as-chair-of-its-board-of-directors/ 2023-06-12T14:05:52+00:00 https://www.synconaltd.com/news-insights/news/anaveon-presents-updated-data-from-the-phase-i-ii-study-of-anv419-during-the-sitc-annual-meeting/ 2022-11-29T11:04:03+00:00 https://www.synconaltd.com/news-insights/news/publication-in-nature-chemistry-demonstrates-the-benefits-of-native-mass-spectrometry-in-the-interrogation-of-target-ecosystems-and-drug-discovery/ 2022-11-11T09:46:39+00:00 https://www.synconaltd.com/news-insights/news/freeline-reports-third-quarter-2022-financial-results-and-corporate-update/ 2022-12-01T09:33:23+00:00 https://www.synconaltd.com/news-insights/news/syncona-half-year-results-for-the-period-ending-30-september-2022/ 2022-11-17T07:05:18+00:00 https://www.synconaltd.com/news-insights/news/purespring-chief-executive-officer-richard-francis-appointed-chief-executive-officer-of-teva-pharmaceutical-industries-ltd/ 2022-11-28T17:46:46+00:00 https://www.synconaltd.com/news-insights/news/freeline-receives-approval-to-transfer-to-nasdaq-capital-market/ 2022-11-30T07:54:34+00:00 https://www.synconaltd.com/news-insights/news/anaveon-appoints-dr-eduard-gasal-as-chief-medical-officer/ 2023-06-12T14:05:50+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-handover-of-first-clean-rooms-of-new-stevenage-uk-manufacturing-facility/ 2022-11-30T12:33:09+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-to-present-early-proof-of-concept-of-safety-and-clinical-activity-of-clonal-neoantigen-reactive-t-cells-at-the-esmo-immuno-oncology-annual-congress-2022/ 2022-12-01T07:47:00+00:00 https://www.synconaltd.com/news-insights/news/positive-initial-clinical-data-from-the-b-lieve-dose-confirmation-trial-for-flt180a-in-hemophilia-b-presented-at-the-international-society-on-thrombosis-and-haemostasis-congress/ 2022-12-01T09:48:38+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-presents-encouraging-phase-i-iia-update-on-clonal-neoantigen-reactive-t-cells-in-advanced-nsclc-and-melanoma-at-esmo-io-congress-2022/ 2022-12-06T11:05:36+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-pivotal-phase-2-felix-clinical-trial-has-met-primary-endpoint-at-interim-analysis/ 2022-12-09T06:33:58+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-receive-70-million-in-milestone-payments-from-blackstone-life-sciences/ 2022-12-09T06:34:08+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-pricing-of-public-offering/ 2022-12-09T06:35:36+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-clinical-data-updates-at-the-american-society-of-hematology-ash-annual-meeting-2022/ 2022-12-12T15:05:32+00:00 https://www.synconaltd.com/news-insights/news/swanbio-therapeutics-initiates-first-in-human-study-of-aav-gene-therapy-for-adrenomyeloneuropathy/ 2022-12-15T13:05:56+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference/ 2022-12-20T13:44:48+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-partial-exercise-of-underwriters-option-to-purchase-additional-adss/ 2022-12-21T21:26:57+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-collaboration-with-cabaletta-bio-for-use-of-autolus-safety-switch-system-in-cell-therapies-for-autoimmune-disease/ 2023-01-09T12:10:51+00:00 https://www.synconaltd.com/news-insights/news/freeline-publishes-preclinical-proof-of-concept-data-for-flt190-its-aav-gene-therapy-candidate-for-fabry-disease-in-the-nature-journal-gene-therapy/ 2023-01-19T13:10:05+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-board-changes/ 2023-01-20T12:09:24+00:00 https://www.synconaltd.com/news-insights/news/anaveon-doses-first-patient-in-a-phase-i-ii-study-of-anv419-as-monotherapy-or-in-combination-with-check-point-inhibitors-in-patients-with-advanced-melanoma/ 2023-02-02T08:45:28+00:00 https://www.synconaltd.com/news-insights/news/third-quarter-update-fy2022-3/ 2023-02-07T07:00:25+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-closing-of-sale-of-its-cmc-focused-german-subsidiary/ 2023-02-10T12:28:30+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-full-year-2022-financial-results-and-operational-progress/ 2023-03-07T12:05:05+00:00 https://www.synconaltd.com/news-insights/news/achilles-reports-q3-2022-financial-results-and-business-highlights/ 2023-03-07T12:07:53+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-has-no-business-relationship-with-silicon-valley-bank/ 2023-03-13T11:05:31+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-resignation-of-chief-financial-officer/ 2023-03-14T11:27:49+00:00 https://www.synconaltd.com/news-insights/news/anaveon-announces-first-patient-dosed-with-anv419-in-a-phase-i-ii-study-of-anv419-in-patients-with-multiple-myeloma/ 2023-03-16T10:25:42+00:00 https://www.synconaltd.com/news-insights/news/anaveon-announces-presentation-of-a-novel-development-compound-at-the-2023-american-association-for-cancer-research-annual-meeting/ 2023-03-23T09:41:09+00:00 https://www.synconaltd.com/news-insights/news/resolution-expands-its-cmc-capabilities-with-key-hires/ 2023-03-30T10:10:20+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-publication-in-molecular-therapy/ 2023-04-04T12:35:51+00:00 https://www.synconaltd.com/news-insights/news/mosaic-therapeutics-closes-28m-series-a-funding-and-appoints-brian-gladsden-as-ceo/ 2023-05-02T15:28:43+00:00 https://www.synconaltd.com/news-insights/news/syncona-appoints-roel-bulthuis-as-managing-partner/ 2023-04-05T10:06:38+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-announces-new-phase-of-growth-with-move-to-new-facilities-and-team-expansion-to-support-portfolio-progress/ 2023-04-19T09:00:05+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-host-virtual-capital-markets-day/ 2023-04-25T12:04:02+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-announces-grant-of-us-patent-covering-the-treatment-of-patients-with-an-immunotherapy-targeting-neoantigens-based-on-tumor-hla-status/ 2023-04-25T12:09:45+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-data-from-auto1-22-trial-in-pediatric-acute-lymphoblastic-leukemia-in-an-oral-presentation-at-the-ebmt-49th-annual-meeting/ 2023-04-27T09:09:35+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-publication-in-molecular-therapy-nucleic-acids/ 2023-05-02T16:20:36+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-selects-cardinal-health-as-u-s-commercial-distribution-partner/ 2023-04-27T12:20:48+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-asco/ 2023-04-27T12:22:14+00:00 https://www.synconaltd.com/news-insights/news/resolution-appoints-liver-disease-expert-dr-clifford-a-brass-as-chief-medical-officer/ 2023-05-02T09:18:22+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-first-quarter-2023-financial-results-and-operational-progress/ 2023-05-04T12:17:51+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-new-immunogenicity-prediction-application-of-its-ai-powered-peleus-platform-uniquely-identifies-the-most-potent-t-cell-antigens/ 2023-06-12T14:05:53+00:00 https://www.synconaltd.com/news-insights/news/swanbio-therapeutics-confirms-substantial-burden-of-disease-of-adrenomyeloneuropathy-amn-in-both-men-and-women/ 2023-05-10T12:24:13+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-reports-first-quarter-2023-financial-results-and-recent-business-highlights/ 2023-05-10T12:24:09+00:00 https://www.synconaltd.com/news-insights/news/freeline-completes-ads-ratio-change/ 2023-05-12T14:13:05+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-pivotal-phase-2-felix-study-of-obe-cel-in-adult-r-r-b-all-selected-for-an-oral-presentation-at-eha/ 2023-05-12T12:07:21+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-announces-appointment-of-new-board-chair-and-series-b-extension/ 2023-05-15T08:04:04+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-presents-positive-results-from-pivotal-phase-2-felix-study-in-adult-r-r-b-all-at-asco/ 2023-06-13T08:09:19+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-at-2023-jefferies-healthcare-conference/ 2023-06-02T15:05:46+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-hold-analyst-call-to-highlight-data-at-asco-from-the-pivotal-phase-2-felix-study-of-obe-cel-data-in-adult-r-r-b-all/ 2023-06-03T11:53:14+00:00 https://www.synconaltd.com/news-insights/news/freeline-reports-first-quarter-2023-financial-results-and-business-highlights/ 2023-06-03T11:46:21+00:00 https://www.synconaltd.com/news-insights/news/freeline-granted-ilap-designation-in-united-kingdom-by-mhra-for-flt201-an-investigational-gene-therapy-for-the-treatment-of-gaucher-disease/ 2023-06-03T11:51:14+00:00 https://www.synconaltd.com/news-insights/news/autolus-to-hold-annual-general-meeting-agm-of-shareholders-on-friday-june-30-2023/ 2023-06-06T11:17:42+00:00 https://www.synconaltd.com/news-insights/news/beacon-therapeutics-launches-with-96-million-120-million-to-develop-a-new-generation-of-gene-therapies-for-retinal-diseases-resulting-in-blindness/ 2023-06-12T15:31:54+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-to-present-at-upcoming-conferences-2023/ 2023-06-13T16:31:12+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-signs-a-collaboration-exclusive-option-and-license-agreement-with-astrazeneca-to-develop-manufacture-and-commercialize-engineered-treg-cell-therapies-for-autoimmune-diseases/ 2023-06-13T17:45:22+00:00 https://www.synconaltd.com/news-insights/news/syncona-full-year-results-for-the-12-months-ended-31-march-2023/ 2023-06-15T06:05:55+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-presents-positive-results-from-auto4-in-relapsed-refractory-trbc1-positive-peripheral-t-cell-lymphoma/ 2023-06-16T11:22:19+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-strengthens-its-board-with-the-appointment-of-dr-robert-iannone-as-a-non-executive-director/ 2023-06-20T11:18:23+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-strengthens-its-team-with-senior-appointments/ 2023-06-26T07:45:58+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-first-patient-dosed-with-its-novel-gene-therapy-candidate-for-gaucher-disease-and-unveils-research-program-in-gba1-linked-parkinson-s-disease/ 2023-06-26T11:59:30+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-publication-in-cancer-immunology-research/ 2023-07-06T11:42:08+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-a-publication-in-nature-medicine-on-obe-cel-in-pediatric-acute-lymphoblastic-leukemia/ 2023-07-06T11:15:12+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-strengthens-its-executive-team-with-the-appointment-of-simon-ramsden-as-chief-financial-officer/ 2023-07-10T07:40:18+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-report-second-quarter-2023-financial-results-and-host-conference-call-on-august-3-2023/ 2023-07-19T11:30:25+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-appointment-of-robert-f-dolski-as-chief-financial-officer/ 2023-07-19T13:49:56+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-expands-leadership-team-with-two-new-appointments/ 2023-08-02T08:12:03+00:00 https://www.synconaltd.com/news-insights/news/purespring-therapeutics-appoints-sachin-kelkar-as-cfo-following-appointment-of-julian-hanak-as-ceo/ 2023-08-02T09:22:20+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-second-quarter-2023-financial-results-and-operational-progress/ 2023-08-04T11:30:17+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-reports-second-quarter-2023-financial-results-and-recent-business-highlights/ 2023-08-04T11:36:27+00:00 https://www.synconaltd.com/news-insights/news/fy2023-4-first-quarter-update/ 2023-08-10T06:20:42+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-appoints-dr-amir-hefni-as-chief-executive-officer/ 2023-08-14T08:33:28+00:00 https://www.synconaltd.com/news-insights/news/freeline-reports-second-quarter-2023-financial-results-and-business-highlights/ 2023-08-15T11:12:21+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-data-from-auto1-22-trial-in-pediatric-acute-lymphoblastic-leukemia-published-in-the-journal-blood/ 2023-10-25T16:00:54+00:00 https://www.synconaltd.com/news-insights/news/purespring-appoints-fredrik-erlandsson-as-chief-medical-officer-and-peter-mulcahy-as-chief-people-officer/ 2023-09-06T13:53:33+00:00 https://www.synconaltd.com/news-insights/news/update-on-gyroscope-and-associated-milestone-payments/ 2023-09-11T08:16:06+00:00 https://www.synconaltd.com/news-insights/news/forcefield-therapeutics-appoints-john-tsai-md-as-chief-executive-officer/ 2023-09-27T08:35:20+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-adds-mark-namchuk-phd-to-scientific-advisory-board/ 2023-09-27T08:47:13+00:00 https://www.synconaltd.com/news-insights/news/launch-of-share-buyback-programme/ 2023-09-29T08:06:21+00:00 https://www.synconaltd.com/news-insights/news/share-buyback-programme/ 2023-09-29T08:08:14+00:00 https://www.synconaltd.com/news-insights/news/clade-therapeutics-announces-the-acquisition-of-gadeta-b-v/ 2023-10-02T14:20:12+00:00 https://www.synconaltd.com/news-insights/news/freeline-announces-positive-initial-clinical-data/ 2023-10-25T13:42:01+00:00 https://www.synconaltd.com/news-insights/news/swanbio-advances-to-higher-dose-cohort-in-first-in-human-study-of-gene-therapy-for-adrenomyeloneuropathy/ 2023-10-04T13:03:15+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-report-third-quarter-2023-financial-results-and-host-conference-call-on-november-2-2023/ 2023-10-11T11:59:49+00:00 https://www.synconaltd.com/news-insights/news/anaveon-announces-poster-presentation-at-the-2023-european-society-for-medical-oncology-annual-meeting/ 2023-10-25T13:41:30+00:00 https://www.synconaltd.com/news-insights/news/swanbio-evolves-leadership-team-with-appointment-of-executive-chair-and-chief-operating-officer/ 2023-10-16T10:35:25+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-new-clinical-data-for-flt201-in-gaucher-disease-in-oral-presentation-at-upcoming-esgct-30th-annual-congress/ 2023-10-16T11:05:26+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-host-virtual-event-to-discuss-the-company-s-obe-cel-program-in-systemic-lupus-erythematosus/ 2023-10-17T11:48:05+00:00 https://www.synconaltd.com/news-insights/news/freeline-presents-positive-new-data-from-phase-1-2-galileo-1-trial-of-flt201-its-novel-gene-therapy-candidate-in-gaucher-disease-at-esgct-30th-annual-congress/ 2023-10-25T13:40:12+00:00 https://www.synconaltd.com/news-insights/news/anaveon-announces-presentation-of-anv600-preclinical-data-supporting-combination-therapy-with-therapeutic-pd-1-inhibitors/ 2023-11-01T09:53:06+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-participation-in-upcoming-conferences/ 2023-11-06T14:43:26+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-founders-present-clinical-proof-of-concept-for-macrophage-cell-therapy-in-end-stage-liver-disease-at-aasld/ 2023-11-13T09:34:03+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-reports-third-quarter-2023-financial-results-and-recent-highlights/ 2023-11-14T09:55:22+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-third-quarter-2023-financial-results-and-business-updates/ 2023-11-14T09:53:15+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-host-analyst-investor-event-at-the-american-society-of-hematology-ash-annual-meeting-2023/ 2023-11-15T12:08:28+00:00 https://www.synconaltd.com/news-insights/news/syncona-half-year-results-for-the-period-ending-30-september-2023/ 2023-11-16T07:00:10+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-expands-leadership-team-with-the-appointment-of-melissa-faris-as-chief-business-officer/ 2023-11-16T08:04:23+00:00 https://www.synconaltd.com/news-insights/news/syncona-to-acquire-freeline-therapeutics/ 2023-11-22T12:36:23+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-submits-biologics-license-application-to-u-s-food-and-drug-administration-for-obecabtagene-autoleucel-obe-cel-for-patients-with-relapsed-refractory-r-r-adult-b-cell-acute-lymphoblastic-leukemia-all/ 2023-11-27T12:06:21+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-presents-clinical-data-updates-at-the-american-society-of-hematology-ash-annual-meeting-2023/ 2023-12-11T10:43:03+00:00 https://www.synconaltd.com/news-insights/news/anaveon-announces-publication-of-anv419-phase-i-data-in-the-journal-for-immunotherapy-of-cancer/ 2023-12-14T09:00:43+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-announces-publication-of-nature-cancer-comment-on-strategy-for-improved-neoantigen-immunogenicity-prediction/ 2023-12-18T12:54:01+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announced-changes-to-its-board-of-directors/ 2024-04-02T08:13:32+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-the-appointment-of-robert-w-azelby-to-its-board-of-directors/ 2024-01-10T12:24:54+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-publication-in-acs-chemical-biology/ 2024-01-23T12:16:57+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-acceptance-of-biologics-license-application-for-obecabtagene-autoleucel-obe-cel-as-a-potential-treatment-for-relapsed-refractory-adult-b-cell-acute-lymphoblastic-leukemia-all/ 2024-02-01T09:55:42+00:00 https://www.synconaltd.com/news-insights/news/beacon-announces-unmasked-three-month-data-from-phase-2-skyline-trial-of-agtc-501-for-x-linked-retinitis-pigmentosa/ 2024-02-01T10:13:42+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-submits-biologics-license-application-to-u-s-food-and-drug-administration-for-obecabtagene-autoleucel-obe-cel-for-patients-with-relapsed-refractory-r-r-adult-b-cell-acute-lymphoblastic-leukemia-all-1/ 2024-02-01T10:01:37+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-clinical-data-updates-at-the-american-society-of-hematology-ash-annual-meeting-2023-in-two-oral-presentations-and-two-poster-presentations/ 2024-02-01T10:06:34+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-to-present-at-the-10th-annual-immuno-oncology-360-conference/ 2024-02-05T12:09:52+00:00 https://www.synconaltd.com/news-insights/news/fy2023-4-third-quarter-update/ 2024-02-08T07:14:59+00:00 https://www.synconaltd.com/news-insights/news/biontech-and-autolus-announce-strategic-car-t-cell-therapy-collaboration-to-advance-pipeline-and-expand-late-stage-programs/ 2024-02-08T11:35:29+00:00 https://www.synconaltd.com/news-insights/news/beacon-therapeutics-announces-positive-12-month-data-from-phase-2-skyline-trial-of-agtc-501-in-patients-with-x-linked-retinitis-pigmentosa/ 2024-02-08T13:26:00+00:00 https://www.synconaltd.com/news-insights/news/autolus-announces-pricing-of-underwritten-offering/ 2024-02-08T12:21:58+00:00 https://www.synconaltd.com/news-insights/news/freeline-shareholders-approve-acquisition-by-syncona/ 2024-02-12T17:08:26+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-publication-in-nature-communications/ 2024-02-22T12:10:25+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-report-full-year-2023-financial-results-and-business-updates-on-march-14-2024/ 2024-02-29T12:04:54+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-publication-in-blood-cancer-journal/ 2024-03-11T11:18:45+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-receives-medicines-and-healthcare-products-regulatory-agency-mhra-certification-for-nucleus-commercial-manufacturing-site/ 2024-03-12T11:15:44+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-full-year-2023-financial-results-and-business-updates/ 2024-03-14T11:05:41+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-changes-to-its-board-of-directors/ 2024-04-02T08:14:03+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-acceptance-of-marketing-authorization-application-maa-by-the-european-medicines-agency-ema/ 2024-04-02T13:07:42+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-provides-interim-phase-i-iia-update-on-clonal-neoantigen-reactive-t-cells-in-advanced-nsclc-and-melanoma-including-first-patients-dosed-with-enhanced-host-conditioning/ 2024-04-05T15:14:20+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-reports-fourth-quarter-and-year-end-2023-financial-results-and-recent-business-highlights/ 2024-04-05T15:15:39+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-expands-scientific-advisory-board-with-the-appointment-of-sarah-teichmann/ 2024-04-09T08:18:57+00:00 https://www.synconaltd.com/news-insights/news/ascend-acquires-gmp-manufacturing-capacity-in-alachua-florida-enters-long-term-partnership-with-beacon-therapeutics-for-clinical-and-commercial-aav-production/ 2024-04-09T13:55:47+00:00 https://www.synconaltd.com/news-insights/news/century-therapeutics-to-acquire-clade-therapeutics/ 2024-04-11T11:17:17+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-report-first-quarter-2024-financial-results-and-host-conference-call-on-may-14-2024/ 2024-04-23T16:08:46+00:00 https://www.synconaltd.com/news-insights/news/abstract-for-longer-term-follow-up-and-additional-data-analysis-of-pivotal-phase-2-felix-study-of-obe-cel-for-adult-r-r-b-all-selected-for-an-oral-presentation-at-asco/ 2024-04-24T14:25:28+00:00 https://www.synconaltd.com/news-insights/news/freeline-to-present-new-data-on-its-gaucher-and-parkinson-s-disease-programs-at-the-american-society-of-gene-and-cell-therapy-asgct-27th-annual-meeting/ 2024-04-25T08:02:19+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-highlights-clinical-potential-of-qel-001-and-its-multi-modular-treg-cell-therapy-platform-at-the-american-society-of-gene-and-cell-therapy-asgct-27th-annual-meeting/ 2024-05-03T10:21:35+00:00 https://www.synconaltd.com/news-insights/news/freeline-presents-positive-new-data-from-phase-1-2-trial-of-flt201-its-novel-gene-therapy-candidate-for-gaucher-disease-in-late-breaking-oral-presentation-at-asgct-27th-annual-meeting/ 2024-06-14T11:21:16+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-reports-first-quarter-2024-financial-results-and-recent-business-highlights/ 2024-05-13T11:35:54+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-delay-to-its-first-quarter-2024-earnings-release-and-conference-call/ 2024-05-13T11:35:50+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-first-quarter-2024-financial-results-and-business-updates/ 2024-05-17T11:05:26+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-announces-research-collaboration-with-arcturus-therapeutics-to-explore-second-generation-personalized-mrna-cancer-vaccines/ 2024-05-22T11:38:14+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-to-participate-in-the-jefferies-global-healthcare-conference/ 2024-05-29T08:40:40+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-announces-upcoming-scientific-presentations-at-easl-congress-2024/ 2024-05-29T08:43:02+00:00 https://www.synconaltd.com/news-insights/news/anaveon-announces-ind-approval-of-anv600-001-expand-phase-i-ii-clinical-study/ 2024-05-29T08:44:35+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-advances-qel-001-its-multi-modular-engineered-car-treg-cell-therapy-into-efficacy-cohort-of-liberate-phase-1-2-trial-in-liver-transplant-patients/ 2024-06-14T11:21:49+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-announces-new-breakthrough-clinical-data-for-macrophage-cell-therapy-in-end-stage-liver-disease-at-easl-2024/ 2024-06-14T11:20:39+00:00 https://www.synconaltd.com/news-insights/news/beacon-therapeutics-treats-first-patient-in-vista-registrational-trial-for-agtc-501/ 2024-06-12T14:29:43+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-three-clinical-data-updates-on-obecabtagene-autoleucel-obe-cel-in-relapsed-refractory-r-r-b-cell-acute-lymphoblastic-leukemia-all-patients-at-the-2024-european-hematology-association-eha-congress/ 2024-06-14T11:00:51+00:00 https://www.synconaltd.com/news-insights/news/spur-therapeutics-formerly-freeline-announces-new-name-and-brand/ 2024-06-17T11:05:53+00:00 https://www.synconaltd.com/news-insights/news/syncona-full-year-results-for-the-12-months-ended-31-march-2024/ 2024-06-20T06:00:33+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-to-host-virtual-r-d-webinar-on-liver-disease-with-world-leading-hepatologist-arun-sanyal-m-d/ 2024-06-25T16:03:44+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-receives-mhra-approval-to-commence-phase-i-ii-emerald-study-for-lead-candidate-rtx001/ 2024-06-27T09:53:14+00:00 https://www.synconaltd.com/news-insights/news/spur-therapeutics-presents-promising-new-data-from-its-gba1-parkinson-s-disease-research-program/ 2024-07-01T11:18:57+00:00 https://www.synconaltd.com/news-insights/news/ionctura-announces-expansion-of-roginolisib-clinical-trial-program-to-nsclc/ 2024-07-09T08:11:52+00:00 https://www.synconaltd.com/news-insights/news/spur-therapeutics-completes-enrollment-in-phase-1-2-galileo-1-trial-of-flt201-in-gaucher-disease-and-selects-dose-for-planned-phase-3-trial/ 2024-07-10T08:09:58+00:00 https://www.synconaltd.com/news-insights/news/beacon-therapeutics-raises-170-million-in-series-b-funding-to-advance-development-of-ophthalmic-gene-therapies/ 2024-07-10T08:11:51+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-appoints-experienced-biopharma-leader-luke-beshar-as-independent-chair-of-its-board-of-directors/ 2024-07-11T08:47:24+00:00 https://www.synconaltd.com/news-insights/news/beacon-therapeutics-appoints-lance-baldo-md-as-chief-executive-officer-and-thomas-biancardi-as-chief-financial-officer/ 2024-07-24T11:15:18+00:00 https://www.synconaltd.com/news-insights/news/anaveon-appoints-dieter-weinand-as-chair-of-its-board-of-directors/ 2024-07-30T07:38:33+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-selected-by-fierce-biotech-as-a-fierce-15-winner-for-2024/ 2024-08-06T15:30:12+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-second-quarter-2024-financial-results-and-business-updates/ 2024-08-08T12:47:56+00:00 https://www.synconaltd.com/news-insights/news/first-quarter-update-fy2025/ 2024-08-13T06:07:16+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-presents-clinical-data-update-at-the-society-of-hematologic-oncology-soho-annual-meeting-2024/ 2024-08-27T11:14:33+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-appointment-of-matthias-will-m-d-as-chief-development-officer/ 2024-09-19T11:06:58+00:00 https://www.synconaltd.com/news-insights/news/achilles-therapeutics-announces-strategic-update/ 2024-09-19T11:11:56+00:00 https://www.synconaltd.com/news-insights/news/beacon-therapeutics-presents-36-month-interim-results-from-phase-i-2-horizon-trial-of-agtc-501-in-patients-with-xlrp/ 2024-09-19T15:20:46+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-announces-upcoming-presentations-at-the-american-association-for-the-study-of-liver-disease-aasld-the-liver-meeting-2024/ 2024-10-01T09:28:43+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-expands-development-team-with-key-appointments-in-us-and-uk-and-announces-the-nomination-of-clinical-candidate-against-mc2/ 2024-10-01T09:26:54+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-announces-63-5-million-series-b-financing-and-chair-appointment/ 2024-10-03T06:00:55+00:00 https://www.synconaltd.com/news-insights/news/purespring-therapeutics-raises-80-105-million-in-a-series-b-financing-to-transform-the-treatment-of-kidney-diseases/ 2024-10-09T06:00:06+00:00 https://www.synconaltd.com/news-insights/news/mosaic-therapeutics-appoints-dr-barry-davies-as-cso/ 2024-10-11T16:23:35+00:00 https://www.synconaltd.com/news-insights/news/beacon-therapeutics-announces-positive-24-month-data-from-phase-2-skyline-trial-of-agtc-501-in-patients-with-x-linked-retinitis-pigmentosa/ 2024-10-15T14:08:06+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-presents-clinical-data-update-at-the-2024-lymphoma-leukemia-myeloma-congress/ 2025-10-20T15:33:30+00:00 https://www.synconaltd.com/news-insights/news/spur-therapeutics-showcases-positive-new-data-from-phase-1-2-galileo-1-trial-of-flt201-its-novel-gene-therapy-candidate-for-gaucher-disease-in-oral-presentation-at-esgct-31st-annual-congress/ 2024-10-23T06:06:32+00:00 https://www.synconaltd.com/news-insights/news/purespring-therapeutics-presents-new-preclinical-data-on-novel-gene-therapy-for-iga-nephropathy-at-asn-kidney-week-2024/ 2024-10-28T11:22:17+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-report-third-quarter-2024-financial-results-and-host-conference-call-on-november-12-2024/ 2024-10-29T09:21:36+00:00 https://www.synconaltd.com/news-insights/news/anaveon-announces-presentation-of-new-data-on-development-compounds-anv700-and-anv600-at-the-society-for-immunotherapy-of-cancer-2024-annual-meeting/ 2024-10-30T09:34:02+00:00 https://www.synconaltd.com/news-insights/news/spur-therapeutics-publishes-preclinical-proof-of-concept-data-for-sbt101-its-gene-therapy-candidate-in-adrenomyeloneuropathy-amn/ 2024-10-31T09:55:27+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-to-present-promising-data-from-autologous-and-allogenic-car-treg-programs-at-upcoming-international-congresses/ 2024-11-04T11:39:57+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-present-clinical-data-updates-at-the-american-society-of-hematology-ash-annual-meeting-2024-in-one-oral-presentation-and-three-poster-presentations/ 2024-11-05T14:14:35+00:00 https://www.synconaltd.com/news-insights/news/kesmalea-therapeutics-appoints-robert-johnson-as-ceo-to-lead-development-of-new-class-of-oral-cns-penetrant-protein-degraders/ 2024-11-07T09:14:07+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-fda-approval-of-aucatzyl-obecabtagene-autoleucel-obe-cel-for-adults-with-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia-r-r-b-all/ 2024-11-11T07:06:05+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-announces-new-clinical-and-preclinical-data-showcasing-regenerative-macrophage-therapy-at-aasld-2024/ 2024-11-11T18:41:35+00:00 https://www.synconaltd.com/news-insights/news/slingshot-therapeutics-launches-with-its-first-programme-and-12-5-million-to-accelerate-early-stage-drug-development/ 2024-11-14T07:00:13+00:00 https://www.synconaltd.com/news-insights/news/interim-results-for-the-six-months-ended-30-september-2024/ 2024-11-14T07:29:29+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-appoints-professor-steven-charlton-as-chief-scientific-officer/ 2024-11-15T16:14:03+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-achieves-milestone-for-type-1-diabetes-car-treg-cell-therapy-program/ 2024-11-18T10:25:56+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-announces-approval-of-clinical-trial-application-by-aemps-to-expand-phase-1-2-emerald-study-of-rtx001-into-spain/ 2024-11-20T09:50:03+00:00 https://www.synconaltd.com/news-insights/news/spur-therapeutics-announces-development-candidate-in-parkinson-s-disease-gene-therapy-program/ 2024-12-03T12:07:11+00:00 https://www.synconaltd.com/news-insights/news/beacon-therapeutics-announces-positive-3-month-data-from-phase-2-dawn-trial-of-laru-zova-agtc-501-in-patients-with-x-linked-retinitis-pigmentosa-xlrp/ 2024-12-06T14:19:55+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-announces-presentation-at-keystone-symposia-on-fibrosis/ 2024-12-10T09:15:44+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-presents-clinical-data-updates-at-the-american-society-of-hematology-ash-annual-meeting-2024/ 2024-12-10T09:22:12+00:00 https://www.synconaltd.com/news-insights/news/ionctura-reaches-new-clinical-milestones-in-uveal-melanoma/ 2025-02-12T15:06:52+00:00 https://www.synconaltd.com/news-insights/news/anaveon-appoints-dr-richard-sachse-as-chief-medical-officer/ 2024-12-18T13:39:50+00:00 https://www.synconaltd.com/news-insights/news/yellowstone-biosciences-appoints-dr-ita-o-kelly-previously-executive-director-product-management-at-immunocore-as-its-chief-operating-officer-and-a-member-of-its-leadership-team/ 2025-01-28T11:49:24+00:00 https://www.synconaltd.com/news-insights/news/beacon-therapeutics-granted-fda-regenerative-medicine-advanced-therapy-rmat/ 2025-01-28T13:40:51+00:00 https://www.synconaltd.com/news-insights/news/spur-therapeutics-announces-successful-end-of-phase-2-meeting-with-fda-for-flt201-its-gene-therapy-candidate-for-gaucher-disease/ 2025-02-03T13:37:50+00:00 https://www.synconaltd.com/news-insights/news/third-quarter-results-fy2025/ 2025-02-06T07:01:14+00:00 https://www.synconaltd.com/news-insights/news/spur-therapeutics-announces-positive-data-from-phase-1-2-galileo-1-trial-of-flt201-its-gene-therapy-candidate-for-gaucher-disease-at-worldsymposium/ 2025-02-11T16:17:55+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-appoints-birgitte-volck-as-non-executive-director/ 2025-02-26T08:01:26+00:00 https://www.synconaltd.com/news-insights/news/purespring-therapeutics-appoints-haseeb-ahmad-as-chief-executive-officer/ 2025-10-20T15:33:30+00:00 https://www.synconaltd.com/news-insights/news/ionctura-commences-randomized-phase-ii-study-in-metastatic-uveal-melanoma/ 2025-03-20T12:06:09+00:00 https://www.synconaltd.com/news-insights/news/purespring-therapeutics-granted-european-medicines-agency-ema-orphan-drug-designation/ 2025-04-28T09:49:34+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-license-of-aucatzyl/ 2025-04-28T14:22:21+00:00 https://www.synconaltd.com/news-insights/news/beacon-therapeutics-announces-positive-phase-2-interim-6-month-data-from-dawn-trial-of-laru-zova-in-patients-with-x-linked-retinitis-pigmentosa-xlrp-at-arvo-2025/ 2025-05-07T11:44:40+00:00 https://www.synconaltd.com/news-insights/news/ionctura-commences-randomised-phase-i-ii-study-in-non-small-cell-lung-cancer/ 2025-05-08T08:15:30+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-announces-regenerative-macrophage-therapy-rmt-manufacturing-process-candidate-testing-suite-at-asgct-2025/ 2025-05-14T09:07:57+00:00 https://www.synconaltd.com/news-insights/news/kesmalea-therapeutics-appoints-industry-veteran-tim-clackson-to-board-of-directors/ 2025-05-14T09:57:42+00:00 https://www.synconaltd.com/news-insights/news/slingshot-therapeutics-strengthens-its-team-through-the-appointment-of-ed-savory-as-head-of-chemistry/ 2025-05-20T11:12:25+00:00 https://www.synconaltd.com/news-insights/news/spur-therapeutics-publishes-preclinical-proof-of-concept-data-for-flt201-its-clinical-stage-gene-therapy-candidate-in-gaucher-disease/ 2025-05-27T12:19:53+00:00 https://www.synconaltd.com/news-insights/news/ionctura-bolsters-leadership-team-with-new-appointments/ 2025-06-02T08:44:32+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-achieves-key-milestone-in-its-car-treg-cell-therapy-program-for-inflammatory-bowel-disease/ 2025-06-10T11:31:53+00:00 https://www.synconaltd.com/news-insights/news/spur-therapeutics-presents-positive-new-preclinical-data-on-its-gene-therapy-candidate-for-gba1-parkinson-s-disease-at-2025-gba1-meeting/ 2025-06-06T12:30:13+00:00 https://www.synconaltd.com/news-insights/news/northern-gritstone-invests-in-manchester-spinout-apini/ 2025-06-11T08:02:49+00:00 https://www.synconaltd.com/news-insights/news/beacon-therapeutics-strengthens-leadership-team-with-the-appointment-of-dr-daniel-chung-as-chief-medical-officer/ 2025-06-10T08:23:05+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-to-present-new-preclinical-data-for-its-best-in-class-mc2-program-at-endo-2025/ 2025-07-07T09:46:28+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-announces-first-patient-dosed-and-safety-review-cleared-in-emerald-phase-1-2-clinical-study-of-rtx001-a-first-in-class-regenerative-macrophage-therapy-to-treat-end-stage-liver-disease/ 2025-10-20T15:33:30+00:00 https://www.synconaltd.com/news-insights/news/beacon-therapeutics-completes-enrolment-in-registrational-phase-2-3-vista-trial-of-laru-zova-for-patients-with-xlrp/ 2025-07-09T08:24:28+00:00 https://www.synconaltd.com/news-insights/news/purespring-therapeutics-announce-fda-ind-clearance-for-phase-i-ii-clinical-trial-for-primary-iga-nephropathy-igan/ 2025-07-09T08:39:47+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-presents-positive-preclinical-data-for-its-best-in-class-mc2-program-at-endo-2025/ 2025-07-14T07:34:43+00:00 https://www.synconaltd.com/news-insights/news/purespring-therapeutics-receives-uk-cta-approval-for-phase-i-ii-clinical-trial-of-ps-002-in-patients-with-primary-iga-nephropathy-igan/ 2025-08-05T07:56:40+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-appoints-carol-a-schafer-as-non-executive-director-and-chair-of-the-audit-committee/ 2025-08-06T11:18:58+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-to-host-virtual-r-d-webinar-alongside-world-leading-clinical-hepatologists-prof-jonathan-fallowfield-and-dr-elliot-tapper/ 2025-08-27T08:24:45+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-enters-into-exclusive-collaboration-and-license-agreement-with-genentech-to-develop-and-commercialize-therapies-for-inflammatory-bowel-disease/ 2025-09-02T07:29:37+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-announces-first-patient-dosed-in-phase-i-ii-emerald-study-of-rtx001-for-the-treatment-of-end-stage-liver-disease/ 2025-09-03T07:39:29+00:00 https://www.synconaltd.com/news-insights/news/ionctura-expands-roginolisib-trials-to-the-us-advancing-multi-indication-strategy-in-oncology/ 2025-09-09T10:12:17+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-appoints-lucy-singah-as-chief-financial-officer-and-daniel-kennedy-as-chief-business-officer/ 2025-09-10T08:49:13+00:00 https://www.synconaltd.com/news-insights/news/yellowstone-biosciences-appoints-james-jim-macdonald-as-chief-executive-officer/ 2025-09-16T11:12:00+00:00 https://www.synconaltd.com/news-insights/news/spur-therapeutics-presents-updated-phase-1-2-data-on-its-gene-therapy-candidate-in-gaucher-disease-at-esgct-32nd-annual-congress/ 2025-10-07T08:28:28+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-to-present-emerald-study-design-at-the-british-association-for-the-study-of-the-liver-basl-annual-meeting-2025/ 2025-10-07T08:34:25+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-announces-upcoming-presentations-at-the-american-association-for-the-study-of-liver-disease-aasld-the-liver-meeting-2025/ 2025-10-09T09:10:44+00:00 https://www.synconaltd.com/news-insights/news/ionctura-debuts-cambritaxestat-ioa-289-clinical-data-in-patients-with-pancreatic-cancer-at-esmo/ 2025-10-14T08:40:39+00:00 https://www.synconaltd.com/news-insights/news/mosaic-therapeutics-appoints-thomas-fuchs-as-ceo/ 2025-10-20T10:24:12+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-first-patient-dosed-in-phase-1-trial-of-obecabtagene-autoleucel-obe-cel-in-patients-with-progressive-multiple-sclerosis/ 2025-10-20T15:33:28+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-presents-clinical-data-updates-at-the-american-college-of-rheumatology-convergence-2025/ 2025-10-27T15:56:00+00:00 https://www.synconaltd.com/news-insights/news/slingshot-therapeutics-strengthens-team-by-appointing-john-isaac-as-chief-scientific-officer-and-bobby-soni-as-chief-business-officer/ 2025-11-04T09:09:00+00:00 https://www.synconaltd.com/news-insights/news/resolution-therapeutics-announces-new-data-showcasing-the-potential-of-regenerative-macrophage-therapy-in-treating-cirrhosis-at-aasld-2025/ 2025-11-07T16:25:05+00:00 https://www.synconaltd.com/news-insights/news/mosaic-therapeutics-appoints-dr-stephen-shuttleworth-as-chief-scientific-officer/ 2025-11-17T12:37:13+00:00 https://www.synconaltd.com/news-insights/news/nice-recommends-aucatzyl-obecabtagene-autoleucel-as-a-treatment-option-for-adult-patients-26-years-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia-r-r-b-all/ 2025-11-25T09:11:58+00:00 https://www.synconaltd.com/news-insights/news/ionctura-initiates-phase-i-ii-trial-in-patients-with-myelofibrosis-ahead-of-new-non-clinical-data-at-ash/ 2025-12-09T14:27:30+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-presents-updated-clinical-data-from-the-carlysle-trial-in-patients-with-severe-refractory-systemic-lupus-erythematosus-at-the-american-society-of-hematology-ash-annual-meeting-2025/ 2025-12-09T11:17:20+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-presents-initial-clinical-data-in-pediatric-r-r-b-all-patients-and-other-oncology-data-at-the-american-society-of-hematology-ash-annual-meeting-2025/ 2025-12-09T11:20:55+00:00 https://www.synconaltd.com/news-insights/news/beacon-therapeutics-treats-first-patient-in-landscape-trial-of-laru-zova-in-patients-with-x-linked-retinitis-pigmentosa-xlrp/ 2025-12-16T15:40:16+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-to-evaluate-automated-manufacturing-of-aucatzyl-obe-cel-on-the-cellares-cell-shuttle-platform/ 2026-01-06T15:24:51+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-announces-preliminary-unaudited-fourth-quarter-and-full-year-2025-net-product-revenue-pipeline-advancements-and-outlook-for-2026/ 2026-01-12T13:58:34+00:00 https://www.synconaltd.com/news-insights/news/omass-therapeutics-appoints-jonathan-montagu-as-chair-of-the-board-of-directors/ 2026-01-28T14:15:55+00:00 https://www.synconaltd.com/news-insights/news/spur-therapeutics-presents-new-phase-1-2-data-on-its-gene-therapy-candidate-in-gaucher-disease-at-22nd-annual-worldsymposium/ 2026-02-04T16:12:59+00:00 https://www.synconaltd.com/news-insights/news/altx-therapeutics-launches-into-the-slingshot-accelerator-with-12-55-million-of-funding/ 2026-02-05T07:36:00+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-demonstrates-safety-phenotypic-stability-durability-and-early-efficacy-with-phenotype-locked-car-tregs-in-liberate-phase-1-2-liver-transplant-study/ 2026-03-03T09:27:23+00:00 https://www.synconaltd.com/news-insights/news/quell-therapeutics-initiates-chill-phase-1-2-trial-of-novel-qel-005-car-treg-therapy-in-refractory-rheumatoid-arthritis-and-systemic-sclerosis-following-uk-cta-approval/ 2026-03-03T09:31:55+00:00 https://www.synconaltd.com/news-insights/news/syncona-investment-management-limited-highlights-progress-translating-frontier-science-into-therapeutic-reality-at-capital-markets-day/ 2026-03-19T10:55:56+00:00 https://www.synconaltd.com/news-insights/news/anaveon-appoints-biotech-leader-thaminda-ramanayake-as-chief-executive-officer/ 2026-03-23T11:34:08+00:00 https://www.synconaltd.com/news-insights/news/autolus-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-updates/ 2026-03-30T16:20:28+00:00 https://www.synconaltd.com/news-insights/insights-articles/ 2023-06-12T14:28:42+00:00 https://www.synconaltd.com/news-insights/insights-articles/quell-therapeutics-and-an-emerging-area-of-cell-therapy/ 2021-06-07T12:48:48+00:00 https://www.synconaltd.com/news-insights/insights-articles/found-build-and-fund/ 2021-06-07T12:49:04+00:00 https://www.synconaltd.com/news-insights/insights-articles/founding-quell-therapeutics/ 2021-06-07T13:21:04+00:00 https://www.synconaltd.com/news-insights/insights-articles/building-syncona-s-gene-therapy-platform/ 2021-06-07T12:46:21+00:00 https://www.synconaltd.com/news-insights/insights-articles/an-introduction-to-gene-therapy/ 2021-06-07T12:49:18+00:00 https://www.synconaltd.com/news-insights/insights-articles/introduction-from-quell-therapeutics-ceo-iain-mcgill/ 2021-06-08T09:52:04+00:00 https://www.synconaltd.com/news-insights/insights-articles/quell-the-science-and-the-unmet-medical-need-for-patients/ 2021-06-08T09:49:27+00:00 https://www.synconaltd.com/news-insights/insights-articles/introducing-resolution-therapeutics/ 2021-06-08T10:28:03+00:00 https://www.synconaltd.com/news-insights/insights-articles/introduction-to-purespring/ 2023-06-12T14:05:53+00:00 https://www.synconaltd.com/news-insights/insights-articles/syncona-fy20-martin-murphy-discusses-fy20-results/ 2021-06-08T10:35:08+00:00 https://www.synconaltd.com/news-insights/insights-articles/syncona-fy20-martin-murphy-discusses-the-impact-of-covid-19/ 2021-06-08T10:49:57+00:00 https://www.synconaltd.com/news-insights/insights-articles/syncona-fy20-martin-murphy-discusses-the-outlook-for-syncona/ 2021-06-08T10:52:46+00:00 https://www.synconaltd.com/news-insights/insights-articles/achilles-doses-first-patient/ 2024-09-27T08:46:40+00:00 https://www.synconaltd.com/news-insights/insights-articles/gene-therapy-explained/ 2024-09-27T08:46:23+00:00 https://www.synconaltd.com/news-insights/insights-articles/syncona-s-martin-murphy-and-freddie-dear-quell-series-a-expansion/ 2021-06-08T10:01:16+00:00 https://www.synconaltd.com/news-insights/insights-articles/delivering-transformational-treatments-for-patients/ 2021-06-07T12:47:07+00:00 https://www.synconaltd.com/news-insights/insights-articles/nightstar-testimonials/ 2021-06-07T12:47:38+00:00 https://www.synconaltd.com/news-insights/insights-articles/measuring-the-potential-impact-of-a-gene-therapy-for-patients/ 2021-06-07T12:47:54+00:00 https://www.synconaltd.com/news-insights/insights-articles/achilles-therapeutics-and-the-advent-of-immunotherapy/ 2024-09-27T08:47:09+00:00 https://www.synconaltd.com/news-insights/insights-articles/marie-curie-case-study/ 2021-06-02T17:16:40+00:00 https://www.synconaltd.com/news-insights/insights-articles/uniting-against-dementia-with-alzheimer-s-society/ 2021-06-17T07:35:33+00:00 https://www.synconaltd.com/news-insights/insights-articles/partnering-with-our-charities/ 2021-06-17T07:35:27+00:00 https://www.synconaltd.com/news-insights/insights-articles/anaveon-doses-first-patient/ 2024-06-20T16:31:40+00:00 https://www.synconaltd.com/news-insights/insights-articles/encouraging-diversity-in-the-next-generation-of-scientists/ 2021-06-29T09:13:04+00:00 https://www.synconaltd.com/news-insights/insights-articles/ed-hodgkin-provides-his-perspectives-from-a-career-in-early-stage-biotech/ 2024-06-20T16:37:05+00:00 https://www.synconaltd.com/news-insights/insights-articles/alex-hamilton-on-manufacturing-in-cell-and-gene-therapy-and-the-role-of-development-partnerships/ 2023-06-12T14:05:58+00:00 https://www.synconaltd.com/news-insights/insights-articles/syncona-ceo-martin-murphy-discusses-clade-series-a-financing/ 2024-04-11T11:38:30+00:00 https://www.synconaltd.com/news-insights/insights-articles/ed-hodgkin-and-magdalena-jonikas-discuss-omass-series-b/ 2022-04-28T10:23:41+00:00 https://www.synconaltd.com/news-insights/insights-articles/welcoming-our-first-windsor-fellowship-intern-to-syncona/ 2022-08-11T16:15:46+00:00 https://www.synconaltd.com/news-insights/insights-articles/building-a-global-leader-in-retinal-gene-therapy/ 2024-06-20T16:36:13+00:00 https://www.synconaltd.com/news-insights/insights-articles/scaling-for-growth/ 2023-06-12T14:28:44+00:00 https://www.synconaltd.com/news-insights/insights-articles/good-science-must-survive-in-challenging-markets/ 2023-06-12T14:28:43+00:00 https://www.synconaltd.com/news-insights/insights-articles/leveraging-the-syncona-team-for-our-next-phase-of-growth/ 2023-06-12T14:28:44+00:00 https://www.synconaltd.com/news-insights/insights-articles/launching-beacon-therapeutics/ 2024-06-20T16:32:48+00:00 https://www.synconaltd.com/news-insights/insights-articles/taking-a-proactive-approach-to-portfolio-company-sustainability/ 2023-07-20T08:20:33+00:00 https://www.synconaltd.com/news-insights/insights-articles/modality-precision-is-the-new-precision-in-medicine/ 2023-08-08T12:52:57+00:00 https://www.synconaltd.com/news-insights/insights-articles/expansion-of-our-senior-team/ 2024-06-25T15:04:08+00:00 https://www.synconaltd.com/news-insights/insights-articles/building-a-platform-for-the-next-generation-of-investors/ 2024-01-25T09:05:51+00:00 https://www.synconaltd.com/news-insights/insights-articles/navigating-the-biotech-landscape-a-journey-from-big-pharma-to-innovative-startups/ 2024-02-15T14:02:17+00:00 https://www.synconaltd.com/news-insights/insights-articles/challenges-continue-but-brighter-days-on-the-horizon/ 2024-02-26T21:25:52+00:00 https://www.synconaltd.com/news-insights/insights-articles/introducing-ionctura/ 2024-09-17T08:57:07+00:00 https://www.synconaltd.com/news-insights/insights-articles/a-spotlight-on-our-female-leaders/ 2024-09-04T08:11:41+00:00 https://www.synconaltd.com/news-insights/insights-articles/creating-yellowstone-syncona-s-launch-team-in-action/ 2024-12-06T14:27:36+00:00 https://www.synconaltd.com/news-insights/insights-articles/introducing-slingshot-therapeutics/ 2025-02-06T17:09:55+00:00 https://www.synconaltd.com/news-insights/insights-articles/fellowship-spotlight-series-ellis-kelly/ 2025-07-18T10:59:57+00:00 https://www.synconaltd.com/news-insights/insights-articles/market-review-fundamentals-are-robust-despite-uncertainty/ 2025-07-22T12:11:23+00:00 https://www.synconaltd.com/news-insights/insights-articles/supporting-uk-life-science/ 2025-07-24T08:21:31+00:00 https://www.synconaltd.com/news-insights/insights-articles/a-new-partner-horatio-s-garden/ 2025-08-21T09:52:09+00:00 https://www.synconaltd.com/news-insights/publications-presentations/ 2023-06-12T14:28:42+00:00 https://www.synconaltd.com/news-insights/newsletters/ 2023-09-06T10:13:06+00:00 https://www.synconaltd.com/investors/ 2026-02-05T17:03:40+00:00 https://www.synconaltd.com/investors/results-and-presentations/ 2025-07-02T07:05:45+00:00 https://www.synconaltd.com/investors/rns-and-inside-information/ 2024-06-21T10:58:15+00:00 https://www.synconaltd.com/investors/share-price-centre/ 2023-06-13T14:06:28+00:00 https://www.synconaltd.com/investors/governance/ 2025-07-03T15:05:09+00:00 https://www.synconaltd.com/investors/our-committees/ 2026-03-13T11:12:26+00:00 https://www.synconaltd.com/investors/financial-calendar/ 2025-06-13T12:58:32+00:00 https://www.synconaltd.com/investors/events-calendar/ 2026-02-09T11:28:29+00:00 https://www.synconaltd.com/investors/analysts-and-advisers/ 2025-06-13T12:58:33+00:00 https://www.synconaltd.com/investors/shareholder-information/ 2025-07-01T13:34:50+00:00 https://www.synconaltd.com/investors/shareholder-information/regulatory-publications/ 2025-06-13T13:28:30+00:00 https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/ 2025-06-13T13:28:30+00:00 https://www.synconaltd.com/investors/faqs/ 2025-06-18T09:14:31+00:00 https://www.synconaltd.com/contact/ 2025-06-13T09:23:39+00:00 https://www.synconaltd.com/accessibility/ 2023-09-07T10:52:44+00:00 https://www.synconaltd.com/privacy-cookies/ 2023-06-12T14:12:01+00:00 https://www.synconaltd.com/employee-privacy-notice/ 2023-06-12T14:11:46+00:00 https://www.synconaltd.com/third-party-privacy-notice/ 2025-07-03T12:33:54+00:00 https://www.synconaltd.com/email-alerts/ 2024-01-08T19:23:30+00:00